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SUMMARY
The effect of dexamethasone on human non-small cell lung 
carcinoma ij2 vitro and iri vivo was investigated. 
Dexamethasone caused a significant reduction in growth rate 
in most of the cell lines at normal passage densities with 
the exception of H125 which had an increased growth rate 
in the presence of dexamethasone. In both cases the 
effect was dose dependent. Clonogenicity as a mono­
layer was increased by dexamethasone in all cell lines 
investigated except H125. Cloning efficiency in agar of 
all the cell lines examined was reduced by dexamethasone 
in a dose dependant manner. Significant levels of 
glucocorticoid receptor were found in all cell lines 
investigated. PA activity was lowered by dexamethasone 
in all cell lires except H125 where it was raised though 
not significantly.
Some alterations in cell surface carbohydrates were found 
to correlate with alterations in cell proliferation. The 
cell lines WIL and H125 were examined for mucin/GAG 
secretion but no mucin secretion was found. Both cell 
lines secreted hyaluronic acid only. Dexamethasone 
increased hyaluronic acid secretion by H125 and decreased 
it in WIL.. Pulmonary surfactant synthesis and secretion 
was increased by dexamethasone in the alyeolar carcinoma 
A549.
Dexamethasone reduced the growth of the murine ROS tumour 
in vivo. The growth of WIL tumour was inhibited totally 
by dexamethasone in a reversible manner although pre­
treatment of WIL cells in vitro with dexamethasone increased 
the frequency of successful tumour takes.
Apparently dexamethasone could increase differentiation and 
reduce malignancy associated properties a manner which 
suggested they were inter-related. The expression of the
differentiated phenotype is also correlated with a 
reduction in cell proliferation. Furthermore the in vivo 
response reflected the in vitro response.
I 1.
GENERAL INTRODUCTION 
Aims of Study
This study has two main aims. Firstly as an investigation 
into the biology of carcinomas^, specif ically lung^
and secondly to investigate the possible utilization of 
dexamethasone in the chemotherapy of lung cancer. These 
two topics are intimately interlinked since the purpose of 
the first area of interest is to investigate the possible 
inter-relationship between malignancy and differentiation 
associated paramaters. It has been proposed that the 
induction of differentiation in tumour cells may be a 
rationale for cancer £ *
Dexamethasone
Dexamethasone is a synthetic glucocorticoid (Fig 1). 
Glucocorticoids are synthesised in the adrenal cortex 
under the control of the anterior pituitary hormone 
adenocorticotrophichormone (ACTH) which stimulates their 
synthesis by increasing the conversion of cholesterol to 
pregnenolone, the rate limiting step in steroid hormone 
synthesis. As the name suggests a major function of 
the hormones is to control glucose levels. Basically, 
the glucocorticoids cause glucose levels to be maintained 
by stimulating the formation of glucose and diminishing 
its utilization. Increased excretion of nitrogen occurs 
as the glucose levels increase indicating that protein 
is converted to carbohydrate. However the glucocorticoids 
have other actions also some of which may be just as 
important as its metabolic effects. They do have some 
mineralocorticoid activity but this is of little importance 
physiologically. One of their most interesting effects 
is on lymphoid tissue where their administration causes 
a reduction in mass which may be associated with 
lympholysis. One of their best documented actions is 
inhibition of inf lammat ionj, As well as inhibiting oedema,
)
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capillary cul<a+<=»-t-»oA and fibroblast proliferation and 
deposition of collagen. In the plasma 90% or more of 
cortisol is reversibly bound to protein under normal 
circumstances. The binding is accounted for by two 
fractions.jone is corticosteroid binding globulin (CBG) 
and the other is plasma albumin. The globulin has high 
affinity but low total binding capacity; the albumin 
has low affinity but relatively large binding capacity 
(1 ).
The Need for New Chemotherapeutic Agents in the Treatment 
of Lung Cancer
The present role of cytotoxic chemotherapy in the treatment 
of lung cancer is very limited. A number of major 
problems exist that have to be answered. The first and 
most important of these is that some types of lung cancer 
do not respond to chemotherapy. This is due to one of 
two features, an inherent drug resistance in the neoplasm 
or an acquired resistance following treatment.
At present there are two approaches being used to 
circumvent this problem. One is to use two drugs in 
combination thus overcoming resistance. Another is to 
give the drug with an agent that will aid drug uptake, 
reduce drug efflux or act by some other means so increasing 
cytotoxicity.
However there are other avenues being investigated that 
do not involve the direct killing of the tumour cells. 
Inhibition of angiogenesisf the process by which tumours 
obtain the blood supply essential for the±r~growthPis 
one. Another is to inhibit invasion or metastdsis and 
so making treatment by surgery easier.
A more novel approach is to induce differentiation and 
reduce the malignancy of the tumour. This and the 
aforementioned approaches have the added bonus that they 
are target specific, non-cytotoxic and have reduced side 
effects.
)
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1. GLUCOCORTICOID MODULATION OF CELL PROLIFERATION AND
CLONOGENICITY; RELATIONSHIP TO GLUCOCORTICOID RECEPTOR 
CONTENT
INTRODUCTION
1.1 Modulation of Cell Proliferation
It is well established that glucocorticoids modulate cell 
proliferation' (2). In 1965 Ruhman and Berher noted
that mouse fibroblasts in vitro had reduced growth rates 
when co(tisone was present (3). Work since then has 
indicated that donor species, tissue origin, cell type, 
cell density and glucocorticoid concentration determine 
how cell proliferation is modified by glucocorticoids 
(4, 5, 6). Viral transformation can also alter the 
response to glucocorticoids. The human fetal lung 
fibroblast lines WI-38 and WI-26 are stimulated when 
hydrocortisone is present but when transformed with SV 40 
their neoplastic counterparts show a reduction in growth.
Much time however has been spent on the effect of 
glucocorticoids upon material derived from neoplastic tissue 
especially human. Using in vitro techniques with cells at 
high density it has been found that lung alveolar carcinoma, 
A549, (7) and lymphoma cells (8) had reduced growth rates
when incubated with dexamethasone. However mammary fibro­
adenoma cells (9) were stimulated by hydrocortisone. It 
should be noted however that it is very difficult to obtain 
cell lines from malignant breast cells and that often the 
cell type grown is derived from normal or benign tissue. 
Vlithin this department dexamethasone was found to stimulate 
growth of early passage human gliomas at low cell densities 
while inhibiting growth at high densities though only with 
high concentrations of^drug (10, 11). It is important 
therefore that the density of the cells used in the 
experiments is taken into account when comparing results.
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1.2 Modulation of Proliferation and Glucocorticoid 
Receptor Number
The cell type most widely investigated has been melanoma 
both in vitro and in vivo^human and non-human. This 
tumour type grows well in culture and many cell lines exist. 
Most investigations have attempted to correlate 
glucocorticoid presence with modulation of proliferation.
Bhevkc?o and colleagues using the murine B16 melanoma in mice 
found that cytosolic receptors with levels from 44 to 200 
fmol mg-1 of protein and Kd's ranged from 2 to 43 nM. 
Administration of various glucocorticoids in different doses 
and regimes showed a singaficant inhibition in mean tumour 
diameter and in animal survival times compared to controls. 
With higher doses of drug evidence of an increase in the 
number of pulmonary .odules was seen though there was no 
evidence of pulmonary metastases (12). Similar results 
were seen with the RPMI 34 60 Syrian Hamster melanoma in vitro. 
The authors indicated that hydrocortisone and triamcinolone 
acetonide caused growth inhibition and that 1.0 jiMv 
progesterone overcame this effect indicating that the ' 
glucocorticoids action was through a specific receptor.
More interestingly^limited exposure of the cells to 
dexamethasone failed to trigger the growth inhibition 
suggesting continuing presence of the drug is essential (13). 
The human malignant melanoma cell line NEL had 
glucocorticoid receptors with Kd InM and 247 fmol mg  ^ of 
protein. A 30% inhibition in growth was seen with a 
continuous incubation of drug (triamcinolone acetonide) for 
72 hours. Progesterone reversed this inhibition (14).
One of the best studies has been with Braunschweiger et al 
using rat, murine and xenograft tumour models (15). 
Glucocorticoidj^was found with a range of 107-14 fmol mg 
of protein. Following acute high dose injection of 
dexamethasone (lOmg kg every 6 hours, 4 doses) there was 
a reduction in glucocorticoid receptor and tumour labelling 
index. Furthermore the dexamethasone response was directly 
correlated to the saturable glucocorticoid receptor whether
assays;
receptor, were carried out in mice, rats, or athymic nude 
mice. The lung alveolar carcinoma previously mentioned,
A549; (7) also had a glucocorticoid receptor Kd of 7.5nM
and a level of 570 fmol mg  ^ of protein. Dexamethasone at 
.a concentration of 40^M caused a 44% inhibition of growth. 
Progesterone at 100-fold molar excess could only partially 
inhibit the action of dexamethasone. However, in a review 
of the literature Homo-Delarche found no clear correlation 
between the level of glucocorticoid receptor and the in vitro 
response in normal and neoplastic lymphoid tissue but in vivo 
attempts at correlation were more successful (16). 
Glucocorticoids can mediate their action on cells by 
permissive effects i.e. not directly through glucocorticoid 
v~ece.pK>v'mediated effects. For example Gospodarowicz reported the 
potentiation of fibroblast growth factor induced 
proliferation by hydrocortisone in 3T3 cells (17). Much 
evidence also exists for permissive effects being mediated 
through the regulation of cells responsiveness to a second 
hormone by altering the number of the second hormone's 
receptor. Steroids have also been found to induce 
production of a growth stimulatory factor. WI-38 cells 
after steroid incubation produce a growth factor that acts 
upon Wl-38 cells in an autocrine fashion to stimulate 
growth and saturation density (18).
1.3 Steroid Receptors in Lung
A survey of the organs of 28 day old fetal rabbits found
that the lungs had a higher concentration of glucocorticoid, 
430 fmol mg"*1. of protein, with respect to other tissues, 
the next highest being placenta with 260 fmol mg of 
protein. There was no significant difference in the othe^- 
tissues examined (19). However this study has the drawback 
that whole lung was used and so contains several tissue 
types. Further investigations using isolated fetal rat 
and human cells found glucocorticoid receptors in type II
cells and fibroblasts (20).
Estrogens also directly alter fetal lung maturation (21).
Low doses of estrone and estradiol when with maximal amounts
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of glucocorticoid increase surfactant synthesis, while 
higher levels are inhibitory. Estradiol binds to fetal 
guinea pig (22) and adult rat lung cytosols (23). Human 
fetal and adult lung also bind*estradiol (24, 25) but with 
slightly lower affinity. As with estrogens, androgens also 
bind to the cytosol from fetal rabbit lung (26) with no 
apparent sex difference in androgen binding.
A molecular examination of normal and neoplastic tissue 
revealed a significant number of specific receptors for 
glucocorticoids, estrogen and androgens with an affinity 
for hormone similar to those in other steroid responsive
\ T V-o v''
tissueS(27). GlucocorticoidJ,was present in 82% of normal 
lung specimens and virtually identical to that reported for 
fetal and adult rabbit, rat and human lung. In normal lung 
glucocorticoid Jjresolved into two distinct binding components, 
with adenocarcinoma the receptor number was invera^Jy 
proportional to the degree of tumour differentiation.
Squamous cell carcinoma receptor levels were slightly lower 
Vlith respect to normal tissue. Estrogen receptor was 
evenly distributed between squamous cell and adenocarcinoma 
cytosols with a slightly lower affinity, but higher content 
than normal lung. Androgen receptor resolved into two 
classes in squamous cell carcinoma similar to the situation 
with glucocorticoid receptor in normal tissue. The most 
undifferentiated squamous tumours had a lower androgen 
receptor content and higher affinity. In contrast there 
was no differentiation of androgen receptor content or 
affinity based on tumour grade in adenocarcinoma.
SFurthermore the receptor did not resolve into two distinct 
groups with respect to affinity.
Thus glucocorticoid receptors, and other steroid receptors 
are found in lung at higher levels than in other tissues 
making lung a good target for induction chemotherapy using 
dexamethasone.
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1.4 Growth in Semi-Solid Medium
MacPherson and Montaginer (28) demonstrated that 
transformation of hamster BHK 21 cells by polyoma virus 
facilitated the growth of these cells in agar.
Clonogenicity in agar was shown in correlate with tumour 
take in immuno-suppressed mice (29, 30).
METHODS
The methods stated here are the same as used in the rest of 
experiments unless stated otherwise.
1. Tissue Culture
1.1 Cell Maintenance
Monolayer cultures were fed • with fresh medium every 4 to 
5 days and routinely passaged by washing in PBS with 
ImM EDTA followed by trypsinisation for 10 to 15 minutes at 
37°C with 0.25% trypsin. The cells were resuspended in 
fresh medium and'^Anoculated into new flasks or experimental 
culture dishes. Experimental cells in 24 well plates, or 
50 mm Petri dishes were inc 
atmosphere with 2 or 5% CO2
ubated at 37°C in a humidified
Medium is F10:DMEM (1:1) with 2mM glutamine and the 
appropriate percentage of serum. Sodium bicarbonate was 
also added, the amount depending on the gas mixture being 
used.
1.2 Cell Counting and Viability
Single cell suspensions were counted electronically using a 
Coulter Counter (Model ZB1). Cell viability was determined 
by exclusion of 0.1% trypan blue. In cloning experiments 
colony size was determined using an Artek colony counter.
The conversion of colony size to cells per colony was done 
by counting the number of cells in a colony of known size.
1.3 Cell Freezing
Frozen stocks of all cell lines were maintained in liquid 
nitrogen. Cell suspensions of greater than 1x10^ cells 
ml  ^ in medium containing 10% DMSO were frozen with an 
approximate cooling rate of 1°C minute
1.4 Staining
Monolayer cell preparations were washed with PBS, fixed in 
methanol for 10 minutes and stained with 10% Giemsa or 0.25% 
crystal violet. Excess stain was removed with tap water 
and the stained preparations air dried.
1.5 Mycoplasma Staining
Cultures fixed with 25% acetic acid in methanol were monitored 
by incubating with the fluorescent DNA stain Hoescht 
33258 at 0.05 jagml  ^for 15 minutes at room temperature.
The detection of extranuclear DNA by fluorescence microscopy 
was indicitave of the presence of mycoplasma infection (31).
1.6 Closing Experiments
1.6.1 Monolayer
In these experiments log phase cells were freshly trypsin- 
ized and in^oculated in 60mm petri dishes at a concentration 
of 100 cells per ml After 14 days incubation unless
otherwise stated the clones were fixed, stained and counted 
by eye or an electronic colony counter.
1.6.2 Suspension
4- -1Cells were in..oculated at 10 ml in a top layer of 0.5% 
agar over a 1% agar underlay. Colonies were counted using 
an inverted microscope after approximately 30 days. Agar 
cloning was carried out in 6 well plates. In all cloning 
experiments the serum concentration was 10%.
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1.7 Glucocorticoid Receptor Assay
Plataeu phase cells were trypsinized and washed with PBS 
twice and then resuspended in 2ml. of assay buffer. The 
buffer waslOmM HEPES, 1.5 mM MgCl^ and 10% glycerol (pH 7.4). 
Dithiothreitol (final concentration 0.25 mM) was added prior 
to addition of buffer to cells. To 150 pi of cell 
suspension 50 pi of ligand was added. The 'hot' ligand was 
(1, 2, 4) (n)-(3H) triamcinolone acetate (3O0i mmol 1 ).
The cells were incubated at 20°C for 2 hours. Varying 
concentrations of dexamethasone were added. The remaining 
cell suspension was retained for DNA measurements (32). 
Protein content was measured by the Bradford assay using 
bovine serum albumin as the standard (33). The bound ligand 
was separated from the free using a Millipore filtration 
system apparatus as described by Laing et al (34). The 
bound ligand is retained on the Millipore filter and the free 
liganeipasses through. The filters are then counted in a 
scintillation counter. Another aliquot is then placed 
directly onto a clean filter and counted; this gives the 
total ligandavailable for binding. The results are 
calculated using a computer programme (35) using Scatchard 
plots (36).
1.8 Cell Lines Used
The origin and type of cell lines used are displayed in Table 
1. The pathology of the tumours is that found at initial 
development of the cell line. All the cell lines have been 
passaged at least 50 times and can therefore be regarded as 
continuous cell lines.
RESULTS
1.1 Clonogenicity and Dexamethasone
The effect of dexamethasone on the clonogenecity of four cell 
lines was investigated as a simple assay for cytotoxicity. 
Three of the cell lines had an increased plating efficiency 
in the presence of dexamethasone while the other was
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ORIGIN, 
CELL 
TYPE 
AND 
PATHOLOGY 
OF 
LUNG 
CELL 
LINES 
USE
D
10.
unaffected. The results for WIL are not shown. The 
clonogenicity of A549 and SKMES was maximally stimulated 
at a concentration of 2.6nM. Dexamethasone levels up to and 
including 26 pm were not cytotoxic although dexamethasone 
levels of 0.26 mM and higher abolished colony formation.
In Figure 2 typical results are shown. The clonogenicities 
of A549 and SKMES were stimulated ' 2 and 3 fold
respectively at a concentration of 2.6nM.
The cell line H125 did not respond to dexamethasone with 
respect to clonogenicity.
From these results it is clear that dexamethasone can alter 
the cloning ability of certain human lung cancer cell lines.
This indicates that at the concentrations used dexamethasone
was not cytotoxic. H125 does not respond to dexamethasone 
in these experiments.
1.2 Glucocorticoid Modulation of Proliferation at Regular 
Passage Densities
Growth curves were carried out for each cell line and termini 
cell density and population doubling time determined from
the data. Cells were in oculated in 24 well plates at a
‘l 3 4 -1de. % o f  5 x 10 cm-2 (10 cells ml ).
Dexamethasone was added 24 hours after ini oculation at a
Cor\£G.x\frctffcm of 26pM unless otherwise stated. Medium was
changed every other day and replicate samples trypsinized
and counted. Cells reached confluence within 10 days of
innoculation.
A typical growth curve is shown in Figure 3. An increase 
in doubling time during late exponential growth and a 
decrease in terminal cell density can be seen. The effect 
of dexamethasone upon terminal cell density of SKMES was 
found at non-physiological concentrations of glucocorticoid 
(10 pM), significant reductions were seen with levels 
normally found in vivo (10nM; Figure 4). With a 
dexamethasone concentration of 26nM a 50% reduction in 
terminal cell density was seen.
FIGURE 2 EFFECT OF DEXAMETHASONE UPON
CLONOGENICITY
Cells were cloned at 100 cells ml ^
(5mls) for 16 days. Cultures were 
then fixed and stained and colonies 
containing more than 16 cells counted. 
Results are the mean of triplicates.
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FIGURE 3 EFFECT OF DEXAMETHASONE UPON GROWTH 
OF SKMES AT REGULAR PASSAGE DENSITIES
4 _ iCells were inoculated at 10 ml ^ in
24 plates with or without dexamethasone. 
Cells were counted every other day. 
Results are the mean of triplicates.
SKMES
CELLS (cm *)
DX
0 2 4 6 8 10 12
TIME (days)
FIGURE 4 EFFECT OF DEXAMETHASONE UPON TERMINAL
CELL DENSITY OF SKMES
Late log phase cultures of SKMES were 
incubated with varying concentrations 
of dexamethasone. After 6 days the 
cells were trypsinised and counted. 
Mean + s d (n=3).
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Table 2 presents the data for of all of the cell lines 
investigated. A54 9, L-DAN and WIL all respond in the same 
way with an almost 2-fold increase in doubling time. The 
terminal cell densities of the cell lines are decreased 
also; 4-fold, 6-fold and 6-fold respectively. However the 
two remaining cell lines, H23 and H125, had different 
responses to the presence of dexamethasone. The cell line 
H23's terminal cell density and doubling time was unaffected 
by the glucocorticoid. The growth rate of H125 was 
increased significantly by dexamethasone as was the terminal 
cell density.
Dexamethasone had a profound effect upon the proliferation 
of human lung carcinoma cell lines. All but two of the 
cell lines investigated had a significantly reduced terminal 
cell density and increased doubling time. Of the other 
cell lines investigated H23 was unaffected while H125 had an 
increased terminal cell density and decreased doubling time.
1.3 Glucocorticoid Modulation of Proliferation at Low Cell 
Densities
The effect of dexamethasone upon cell growth at clonal
-2densities (approximately 25 cm ) was investigated using 
cloning experiments as in section 1.2. Cells were plated 
at a concentration of 100 cells ml  ^ (5mls) in 5cm petri 
dishes in the presence of various concentrations of 
dexamethasone. At various time points the experiments were 
stopped, the cultures fixed, stained - crystal violet 
(0.25%) and sized electronically. In Figure 5 an experiment 
using the cell line WIL is shown from a culture 8 days post­
in oculation. As can be seen at higher drug concentrations 
(26 uM) there is a general increase in colony size. . If 
the incubation is allowed to continue for 15 days very 
similar results were seen with an increase in colony size as 
the concentration of dexamethasone increased (Figure 6). 
Converse results were obtained with the cell line H125.
The presence of dexamethasone reduced the growth rate of 
H125 at clonal densities (Figure 7). For all of these 
experiments the effects were found to be dose dependant.
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FIGURE 5 EFFECT OF DEXAMETHASONE UPON GROWTH
OF WIL AT CLONAL CELL DENSITIES AFTER
8 DAYS.
Cells were inoculated at 100 cells 
-1
ml (5mls). After 8 days cultures 
were fixed and colonies sized 
electronically.
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FIGURE 6 EFFECT OF DEXAMETHASONE UPON GROWTH
OF WIL AT CLONAL CELL DENSITIES AFTER
15 DAYS.
Cells were inoculated at 100 cells 
ml  ^ (5mls). After 15 days cultures 
were fixed and colonies sized 
electronically.
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OF H125 AT CLONAL CELL DENSITIES AFTER
15 DAYS.
Cells were inoculated at 100 cells 
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were fixed and colonies sized 
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These results indicate that at clonal cell densities the 
effect of dexamethasone on the cell lines was the opposite 
of that seen at normal cell densities. In summary at 
clonal cell densities the proliferation of WIL is increased 
while that of H125 is decreased.
1.4 Glucocorticoid Receptor Assay
Cells were assayed for glucocorticoid receptor as stated in 
Methods. All the cell lines were found to have significant 
amounts of glucocorticoid receptor (Table 3). The levels 
are very similar to those obtained for lung tissues, both 
biopsies (19, 20, 21, 27) and cell lines (7). There was no 
obvious correlation between .the effect of dexamethasone and 
receptor concentration. The unresponsive cell line with 
respect to proliferation^H23?had measurable glucocorticoid 
receptor number, as did H125. Overall, besides A549, the 
cell lines had more or less similar levels of receptor.
1.5 Effect of Dexamethasone on Clonogenecity in Agar
As stated earlier ability to grow in agar correlates with 
transformation. Thus a reduction in clonogen-lcity in agar 
is indicative of a reduction in the expression of the 
malignant phenotype. Dexamethasone was found to reduce 
colony formation in all three lines investigated. The 
results are shown in Figure 8. As can be seen the biggest 
reduction was achieved with WIL. At a concentration of 
26 pM clonogenecity was inhibited by 97%. This inhibition 
was dose dependent. A most interesting result in these 
experiments was that with H125. Again a dose dependant 
reduction was seen.
DISCUSSION
Dexamethasone was found to have varied effects on 
proliferation. The effect on proliferation depended on 
cell density and cell type. Interestingly, if a cell's 
growth rate was reduced by dexamethasone at regular passage 
density then it was increased at low cell density by the
TABLE 3 GLUCOCORTICOID RECEPTOR CONTENT OF CELL LINES
fmol fmol fmol fmol nM
Cell per 10  ^ mg  ^ pg ^
Line Sample Cells Protein DNA D
WIL 4772 130 309 2117 1.15
A549 6130 190 703 2797 3.36
H125 1070 44 * 116 1098 1.0
H23 578 26 123 729 N.D.
SKMES 1736 70 184 3535 0.82
FIGURE 8 EFFECT OF DEXAMETHASONE UPON AGAR 
CLONING.
-1
Cells (20,000 ml , 2mls) were 
suspended in 1% agar over a 2% base. 
After 30 days the cultures were 
examined for colonies containing 
greater than 16 cells.
Mean + s • 4 (n=6)
R E L A T I V E  CL O N I N G  E F F I C I E N C Y
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drug. The converse was found for the cell line H125 which 
had an increased growht rate and terminal cell density in 
the presence of dexamethasone. Why is there a difference 
at clonal compared to normal cell densities? It may be 
that at clonal cell densities the in vitro system may mimic 
wound repair i.e. the reformation of a confluent sheet of 
cells. At or approaching confluence growth rate would be 
reduced as a confluent sheet of cells is obtained. If 
dexamethasone has a role in wound repair then the results 
obtained with WIL are in line with this hypothesis. In the 
case of H12f} the cell has the opposite response to 
dexamethasone and thus then explains the results seen.
There was no correlation between response to glucocorticoid 
and the presence of glucocorticoid receptor. Receptor was 
found in significant amounts in all cell lines examined and 
the levels found were similar to those reported in the 
literature. Dexamethasone was found to reduce the cloning 
efficiency in agar of the three cell lines investigated, 
thus indicating a reduction in malignancy.
As stated earlier dexamethasone reduced the clonogenecity of 
WIL, A549 and H125 in soft agar. This is interesting since 
in previous experiments H125 responded in a different 
fashion to the other cell lines investigated (an increased 
growth rate and terminal cell density in the presence of 
dexamethasone). This may be explained by the fact that 
properties other than transformation affect growth in agar.
A simple reduction in growth rate may reduce growth in agar. 
In the case of H125 this is an attractive proposition since 
stated earlier (section 1.4) the growth of the cell line is 
inhibited at low cell densities. The cell lines A549 
and WIL have increased growth rate at low cell densities.
The possibility that the reduction in clonogenlcity is due 
to tumour cell kill can be discounted since the clonogenecity 
of these cell lines is not reduced when examined as a 
monolayer (section 1.2).
2. PLASMINOGEN ACTIVATORS AND NEOPLASIA
INTRODUCTION
Plasminogen activators (PA) are a group of serine 
proteases found in nearly all tissues and many body fluids. 
At present the best known function of PA is its involvement 
in the catalyzation of inactive plasminogen to plasmin, 
which digests fibrin clots. The PA group of enzymes 
is divided into 3 types, circulating PA (blood), tissue 
PA (tPA), and urinary PA (u p a ) commonly known as urokinase.
2.1 Elevation of PA Levels and Alteration in PA Type
It is known that PA plays a major role in malignant 
transformation and the spread of cancer but it is important 
to remember that PA also has a major role in many non- 
neoplasty and non-pathological processes (e.g. mammary 
gland involution involves tpA). Hence it is interesting 
to note that some normal biological processes may have 
counterparts in neoplasia e.g. mammary gland involution 
versus invasion and uterine blood supply versus tumour 
angiogenesis.
The PA found in tumour cells has a higher than normal 
amount of urokinase-like activity compared to that of 
normal tissue. This was ascertained by monitoring the 
inhibition of PA activity by antibodies to urokinase.
By this approach it was found that in human lung tumours 
greater than 90% of PA activity is of the urokinase-like 
type compared to 50% in normal tissue (38). Similarly 
in breast carcinomas 80% of PA activity is of the urokinase 
like type compared to 62% in normal breast (39). However 
separation of tumour PA activity into urokinase and non­
urokinase like is over simplistic. Medium from a human 
lung tumour cell line has been reported to have a PA 
activity associated with a protein of molecular weight 
1-2 million daltons which possessed reactivity in all 
antibodies against urokinase (40). Urokinase has a
molecular weight of 70 k daltons. Furthermore 6 different
15.
proteases with PA activity were secreted by MCF-7 breast 
cancer cells. All but one of these was immunologically 
related to urokinase (41).
Compared with normal tissues a variety of human cancers 
show elevated levels of PA. These include carcinoma 
of colon, lung, breast, cervix, prostate and melanoma 
(39, 39, 42, 43). Lung tumour explants release 40 times 
more PA activity into the medium than did normal lung.
In contrast tPA extracted with Triton-X-100 was only about 
3 times greater than in malignant tissue compared to 
normal lung (44). This was taken to indicate the 
importance of secreted PAs in examining differences in 
activity between normal and malignant cells. In summary, 
PA of malignant carcinoma is more likely to be urokinase­
like and released by the cells.
2.2 The Role of Tumorigenesis, Invasion and Metastasis
U^keless et al (45) were first to show that cultured chick 
embryo fibroblasts transformed with Rqots Sarcoma Virus 
(RSV) had increased cell associated PA. It was also 
proven that the increased PA activity was due to 
transformation not virus infection per se by using 
temperature sensitive mutants of RSV. Tumour promoters 
such as phorbol myristate acetate can also increase levels 
of PA in both normal and RSV transformed fibroblasts along 
with morphological changes not associated with a rise 
in PA (46).
The aforementioned data indicate that transformed cells 
have elevated PA levels -<^ witi. their normal
counterparts. However the most important question is 
still unanswered. Does PA have a role in tumorigenesis, 
invasion, or metastasis?
Indirect evidence for these processes does exist. In 
some transformed cell lines secretion of PA has been shown 
to correlate with growth of the cells in soft agar (47), 
their ability to form a tumour in immunosupressed animals
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(48) and their increased rates of migration (49).
Utilizing tumorigenic and non-tumorogenic melanoma, PA 
activity was found to correlate with tumour take in mice.
A highly tumorigenic clone B^59 if grown in the presence 
of bromodeoxyuridine (Br dU) lost its ability to grow 
in mice, had an altered morphological appearance and could 
no longer digest fibrin. These effects were reversed 
when Br dU was removed (50). Thus in this system at 
least PA production was directly related to tumorigenicity.
A more comprehensive study with early passage human gliomas 
and normal glia found that PA production was inversely 
related to the expression of differentiation (51).
In contrast to these results linking PA with tumorigenicity 
Nicolson et al (52) found no significant differences in 
PA activity between B16 melanoma cells with different 
metastatic potentials.
Using human specimens a relationship has been found between 
fibrinolysis and intravascular growth in epidermoid lung 
carcinoma^ More recently Markus and co-workers (54) 
found a significant correlation between tPA levels and 
local invasion in colonic carcinomas. However the same 
workers were unable to demonstrate a relationship between 
PA levels and local invasion in either lung (38) or breast 
cancer (39).
More direct evidence that PA enzymes are involved in 
metastasis has come from experiments involving the 
administration of urokinase to rabbits bearing V2 carcinoma. 
It was shown that there was increased growth and metastasis 
of the tumour in the presence of enzyme (55). The most 
impressive data for the involvement of PA directly in 
the spread of cancer has come from in vitro work by 
^..examining the ability of the human carcinoma HEp3 to cross 
the chorio-allantoic membrane and metastasis into the chick 
embryo lung (56). An antibody specific for human urokinase 
either prevented or strongly inhibited metastasis to the 
lung but had no effect on tumour growth. The authors 
concluded that PA is essential during the early stages
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of metastasis.
Thus there are a number of reasons to suggest that the 
PA/plasmin system may be important in tumour invasion.
Firstly/ as mentioned earlier, PA is involved in normal
/ '
physiological events associated with invasion, morphogenesis 
and tissue reconstruction. Secondly due to the catalytic 
nature of PA and the high level of plasminogen found in 
extracellular spaces, large amounts of plasmin may be 
produced locally. Thirdly, PA appears to be able to 
digest directly components of the basement membrane (57). 
Furthermore there is strong evidence that collagenases 
have a role in invasion and metastasis and it has been 
shown that plasmin activates procOllagenase (58).
2.3 Alteration of PA Activity by Chemicals
If PA is involved in neoplasia then an agent that lowers 
the enzyme's activity may be useful in the treatment of 
cancer. A reduction in PA would indicate an increase 
in differentiation. Rifkin examined the suppressive 
effects of various glucocorticoids on human embryonic 
lung cells in vitro. Inhibition was reversible and the 
growth of the cells was not affected. Dexamethasone 
and B-methasone had the most potent effect almost totally 
abolishing PA activity (59). Dexamethasone regulation 
of PA was also investigated in tumour and embryonic cell 
lines. This study indicated that dexamethasone could 
inhibit, stimulate or have no effect upon PA activity 
(60). A human lung adenocarcinoma cell line had reduced 
PA activity when incubated with dexamethasone (61).
The mechanism of dexamethasone inhibition of PA activity 
has been elucidated with rat hepatoma cells (62). Extracts 
of dexamethasone treated cells were mixed with extracts 
of control cells and a drop in expected PA activity was 
seen indicating that the glucocorticoid induced an inhibitor 
of protease activity. A dexamethasone-resistant variant 
produced no inhibitor.
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Contrary to the above results and hypothesis, elevated 
PA has been indicated as a marker of differentiation in 
normal human bronchal epithelial cells (63). At a 
concentration of 0.4pM Transforming Growth Factor J3 (TGF- 
j3) was found to induce differentiation and cause a 
concomitant increase in PA. However squamous different­
iation is a metaplastic event and not strictly "normal" 
differentiation in the bronch us.
In conclusion, with certain reservations PA activity, 
particularly soluble u p a , may be regarded as a malignancy- 
associated marker for many tumours including non-small 
cell lung carcinoma.
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METHODS
2.1 Measurement of Total Plasminogen Activator
A modification of the chromogenic assay developed by Whur 
et al (64) was used to measure the PA activity. Cells 
were grown to confluence in 24 well plates before the 
assay was carried out. The assay is a two step process 
resulting in an amido-lytic reaction releasing 
p-nitroaniline from the synthetic chromogenic substrate.
Plasmin cleaves the substrate which in the majority of 
the forthcoming experiments is S-2251, H-D-valyl-L-leucyl- 
L-lysine-p-nitroaniline dihydrochloride, and the 
p-nitroaniline released has an absorbance at 405nm.
The absorbance at 405nm is then a direct measure of PA.
This process is schematically presented in Figure 9.
To remove inhibitors within the serum the medium was 
aspirated and the cells washed twice with Hanks' Balanced 
Salt Solution (HBSS) without phenol red. Reaction mixture 
was then added to the cell monolayers. The reaction 
mixture consisted of ImM chromogenic substrate, 1C.U. 
ml-1 of plasminogen, and 0.15 mg ml poly-D-lysine.
All the reagents were dissolved in HBSS. The assay was 
terminated after 2 hours with the addition of 5% acetic 
acid. Two controls are needed one for endogenous PA 
activity within the reagents and the other for general 
protease activity associated with the cells. The 
proteolytic enzyme urokinase^ which also activates
plasminogen.was used as a standard. PA activities were
J -6 -6 
expressed as Ploug Units 10 cells (PU 10 cells).
Experiments were carried out to ascertain what was the
best substrate to measure PA ac tivity. The results
are shown in Figure 10. The substrates S-2288, S-2238,
S-2251 were incubated with 0.5 PU ml of urokinase for
-1
two hours with or without poly-D-lysine (0.15 mg ml ).
As can be seen S-2251 is the best agent although only 
marginally better than S-2288. From data it was
decided that S-2251 was the best substrate for the cells 
under study.
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The incorporation of poly-D-lysine in the reaction mixture 
increased the rate of the reaction by almost 5-fold with 
substrate S-2251.
2.2 Measurement of t-PA Activity
The measurement of t-PA activity was carried out using 
a commercially available kit. . Fibrinogen was added to 
activate any t-PA present along with acidification of 
the assay to remove the effects of any inhibitor present.
A standard curve was used to measure t-PA activity utilizing 
the substrate S-2251 (Flow/Kabivitrum).
RESULTS
2.1 Effect of Dexamethasone upon PA Activity
A number of drugs and hormones were tested for their effect
on PA activity in the cell line SKMES. The most dramatic
reduction was seen with the dexamethasone at a concentration
of 26pM (lOug ml )^ . To examine time dependent reduction
5of PA SKMES cells were plated at a density of 10 cells 
-2cm for 24 hours and dexamethasone (26jjM) then added 
and the cells incubated for the appropriate time. Control 
cells were seeded at the same density at the same time 
and underwent the same manipulation but received r\© 
dexamethasone. The results are shown in Figure 11.
Within 25 hours there was a 90% reduction in PA activity 
in SKMES and by 75 hours this reduction was 95%. Thus 
the greats/part of the reduction was seen within 25 hours 
of incubation with drug. Reduction of PA in SKMES was 
dose dependant (Figure 12). Cells were incubated with 
dexamethasone for 3 days before measuring PA. There 
was a significant decrease at 26pM, a concentration close 
to the expected physiological level. On the basis of 
these results it was decided to use dexamethasone at the 
maximum non-toxic concentration (26pM) and to have an 
incubation period of 3 days.
Of the other cell lines tested 4 had reduced PA activities
FIGURE 11 TIME DEPENDENT REDUCTION OF PA ACTIVITY
IN SKMES BY DEXAMETHASONE.
Post-confluent cultures of cells were 
incubated with or without dexamethasone 
(26pM) for the appropriate time.
Results are expressed as a percentage 
of parallel cultures containing no 
drug.
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FIGURE 12 DOSE DEPENDANT REDUCTION OF PA ACTIVITY
IN SKMES BY DEXAMETHASONE.
Post confluent cultures of SKMES were 
incubated with varying concentrations 
of dexamethasone for 3 days and then 
assayed.
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when incubated with dexamethasone and this effect was 
dose dependant (Table 4). However, not all the cell 
lines sensitive to dexamethasone had the same responsiveness. 
The cell lines A549 and L-DAN were responsive to 
dexamethasone to about the same extent as was SKMES, their 
PA levels being lowered by 98% and 95% respectively.
However, the PA activity of WIL cells was only reduced 
by 75% in the presence of 26jiM dexamethasone. H23 had 
a very low PA activity but this could be lowered by a 
significant amount. At a concentration of 26pM there 
was a 69% reduction of PA activity.
Of all the cell lines examined only one H125 did not have 
its PA activity lowered by dexamethasone (Figure 13).
At a concentration of 26pM there was an increase in PA ,
activity but this was not significant.
2.2 Possible Correlation between PA Activity and State 
of Differentiation
There have been previous reports of an inverse correlation 
between the state of differentiation of neoplastic tissue 
and PA levels; the highe-jr* PA levels accompanied the
a IthoyciK
more, differentiated neoplasm^ The results (Table
5) from this study - ' are from a very small
sample. For example H125 a well differentiated 
adenocarcinoma has the highest PA activity of all the 
lines examined while the undifferentiated H23 has the 
lowest PA of all 3 the adenocarcinoma cell lines examined. 
Thus there seems to be a positive correlation between 
degree of differentiation and PA activity. Unfortunately 
there are too few lines of each of the tissue types to 
allow similar investigations to be made.
2.3 Amount of Activity of the t-PA Type
One cell line WIL was investigated for the presence of 
t-PA. Using fibrinogen as a stimulator and acidification 
of the reaction mixture to break down enz.yme inhibitor 
monolayers were investigated for tPA, none was found.
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TABLE 5 RELATIONSHIP OF P A ACTIVITY WITH
DIFFERENTIATION OF ADENOCARCINOMA CELL LINES
P A Activity
— fi
P U 10 Cells State of Differentiation
H125 23.8 Well differentiated
WIL 9.32 Moderately differentiated
Cell
Line
H23 0.015 Poorly differentiated
FIGURE 13 EFFECT OF DEXAMETHASONE UPON PA ACTIVITY 
IN H125.
Post-confluent cultures of H125 were 
incubated with varying concentrations 
of dexamethasone for 3 days and then 
PA activity was assayed.
Mean + s d (n=3)
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It may be that there is tPA activity present in WIL but 
the assay was unable to detect any activity.
DISCUSSION
Dexamethasone was found to reduce significantly the PA 
activity of 5 out of 6 cell lines investigated. The 
reduction was found to be time dependent with the majority 
of the reduction induced by dexamethasone seen in the 
first 25 hours of addition of drug. Although maximal 
inhibition .  ^was achieved with non-physiological
concentrations of glucocorticoid (26jjM) there was still 
a significant reduction with physiological concentrations 
of glucocorticoid (2.6nM). This indicates that 
dexamethasone is able, in some cell lines, to reduce 
significantly the levels of PA, an enzyme often associated 
with the malignant phenotype. Interestingly the percentage 
inhibition seen with dexamethasone is higher than usually 
reported (59, 61) for glucocorticoids, indicating the 
better efficacy of this reagent with respect to other 
steroids. This could be due' to a number of reasons,; e.g. , 
increased affinity for receptor and little metabolism ' ^ ~ 
of the drug resulting in repeated binding to the receptor 
and low inactivation. Dexamethasone is also more stable 
than other glucocorticoids. One cell line, H125, did 
not have significantly altered PA levels in the presence 
of dexamethasone. At higher concentration of dexamethasone 
(26juM) an increase of about 50% over controls was seen 
but this was not significant. In the presence of 
dexamethasone H125 had increased growth rate and terminal 
density. This is in line with the work of Mira-y-Lopez 
et al who found a correlation between hydrocortisone induced 
inhibition of PA activity and reduction of growth in vivo 
with murine mammary tumours (64). However this correlation 
exists in human non-small cell lung cancer only up to 
a point. The cell line H23's growth rate is unaltered 
in the presence of dexamethasone while its PA is 
significantly reduced (Table 4). But at a general level 
there does seem to be a relationship between alteration 
of PA and proliferation by dexamethasone.
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3. ANGIOGENESIS 
INTRODUCTION
3.1 The Process of Neovascularisation and Its 
Investigation
For a solid tumour to grow beyond a few millimetres in 
diameter requires the establishment of an adequate blood 
supply (65). This process of the ingrowth of new blood 
vessels is known as angiogenesis and almost certainly 
tumour induced. Following the establishment of a blood 
supply a formerly dormant tumour will not only begin to 
grow but will also have the potential to be disseminated 
to other sites via the circulatory system (66). In 1971 
(67) it was demonstrated that angiogenesis may be induced 
by a soluble factor or factors produced by the tumour.
A number of experimental systems exist for investigating 
angiogenesis. The most commonly used are
1. A transparent chamber, inserted into the dermis of
the rabbit ear, hamster cheek pouch or dorsal skin 
of mouse (68, 69, 70).
2. The chorioallantoic membrane (CAM) of 9 to 10 day
old chick embryos (71).
3. The rabbit cornea (72).
All of the aforementioned assays allow direct observations 
of angiogenesis. With these assays complete formation 
of blood vessels is achieved resembling the in vivo 
response. Although it is possible to measure the rate 
of growth and count the number of new capillary sprouts 
by these methods they cannot be considered truly 
quantitative. Another problem is the possibility of 
obtaining a false positive response; that is angiogenesis 
not caused by the test sample but by the carrier (e.g. 
Millipore filters, slow release polymers) or by mechanical 
injury via an inflammatory reaction.
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Although the overall angiogenic response is complex the 
reaction of the endothelial cells in angiogenesis can 
be examined in appropriate experimental systems in vitro. 
Basically the process of neovascular growth with respect 
to the endothelial component can be summarised as follows
Pre-existing endothelial cells become more permeable
• ■ i .
and engorged. ^
Endothelial cells become blebbed, cell junctions loosened 
and there is a general increase in the number of 
cytoplasmic organelles. Due to basement membrane 
disruption endothelial cell processes penetrate into the 
perivascular tissue. The endothelial cells then migrate 
in the perivascular tissue stroma towards the source of 
the stimulus. Division of endothelial cells now occurs.
The labelling index of resting endothelial cells is usually 
about 0.1% but during angiogenic stimulation or embryonic 
development the labelling index can rise to about 40% 
measured in animals.
Finally, maturation of capillary sprouts occurs with 
fibroblastic cells migrating towards the new vessels, 
a basement membrane is set down and this results in a 
reduced overall permeability (73). Endothelial cells 
from various sources have been isolated and cultured e.g. 
human umbilical veins (74), bovine heart and aorta (75) 
and bovine adrena cortex (76).
Cultured endothelial cells form at confluence a 
"cobblestone" monolayer of closely opposed polygonal cells.
The quiescent cells within such monolayers are not 
stimulated to synthesise DNA by the addition of fresh 
serum or other mitogens; however disruption of the 
monolayer stimulates proliferation and migration (77).
Endothelial cell division has been monitored by measuring
3
total cell number (75), incorporation of . Vl thymidine 
into the nucleus (78), total amount of DNA present (79) 
and colony number (80).
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It should be noted that although a great number of factors 
have been shown to stimulate endothelial cell proliferation 
in vitro, only some of these stimulating factors are 
angiogenic when examined in vivo. Conversely, other 
factors are angiogenic when examined in vivo have been 
reported to have either no effect or inhibit endothelial 
cell growth in vitro (81, 82), but some of these factors 
have been found to be stimulatory , when examined
under different assay conditions (83). Zetter has used 
capillary endothelial cells in a migration assay to measure 
angiogenesis (84).
3.2 Tumour Induced Neovascularisation
The proliferation of endothelial cells has been reported 
to be stimulated by tumour cell conditioned medium (79), 
co-culture with sarcoma 180 cells (80), Walker 256 
carcinoma cell homogenates (75) and semi-purified Walker 
256 carcinoma extracts (83).
Since angiogenesis is so important in the establishment 
and growth of solid tumours it may be a possible target 
for chemotherapy of neoplasms. An agent that could 
inhibit angiogenesis may reduce growth and possibly cause 
regression of tumours without affecting normal tissue.
3.3 Modulation of Neovascularisation
This,, as an avenue for chemotherapyjhas^ and is still being 
investigated ,and results have given some hope for the 
future. Taylor and Folkman (85) have demonstrated that 
in vivo angiogenesis can be promoted by heparin and 
inhibited by protamine^a heparin antagonist. Previously 
it had been shown that mast cells accumulated at a tumour 
site before the ingrowth of new capillary sprouts (86) 
and that these cells release heparin (87). The presence 
of heparin caused migration of capillary endothelial cells 
in vitro (88) and also enhanced tumour angiogenesis on 
the CAM (89).
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3.3 cont'd
Protamine inhibited the ability of mast cells or heparin 
to cause angiogenesis (87) and inhibited tumour 
angiogenesis in the chick embryo (85).
Using the CAM as an assay^ background inflammation can 
commonly create false positive results and to get around 
this problem corticosteroid is added to suppress 
inflammation. When added with heparin (90) it was found 
that cortisol abolished angiogenesis. During this study 
it was further shown that the two agents together could 
inhibit tumour growth and there was evidence that this 
approach may cause the regression of some established 
tumours. Heparin and cortisol had no cytostatic effect 
on the examined tumour cells in vivo or in vitro. Further 
the inhibitory effect of the drugs was shown to be on 
growing and not mature blood vessels. However not all 
tumours investigated responded to heparin/cortisol.
Medoxyprogesterone, dexamethasone and corticosterone have 
all been found to inhibit neovascularisation and growth 
of the V-2 carcinoma implanted in the rabbit cornea (91). 
This was accompanied with a concomitant drop in 
collagenolytic activity.
METHODS
The bovine pulmonary artery endothelial cell line, CPAE,
was used to measure the presence of mitogenic factors
by monitoring the effect of tumour cell conditioned medium
on proliferation of the endothelial cells. The cells
A* -2were in^ioculated at a density of 5 x 1 0 cm in 6 well
plates of diameter 35mm. CPAE' s were grown in 15% serum
and were at confluence for at least 4 days before being
used in experiments. Conditioned medium was obtained
in the following way. Tumour cells were allowed to reach
_2
confluence in 75 cm flasks. Cells were then incubated 
with either medium with 5% serum for control conditioned 
medium or medium with 5% serum and 26_pM dexamethasone 
(3 days) for conditioned medium from_dexamet-hasone-t-reated 
ere 11s .
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After this incubation period the medium was aspirated 
and the monolayers washed twice with medium. At this 
point fresh medium (5% serum) was added to the cells and 
incubated for 6 hours. The function of this incubation 
was to remove dexamethasone that is bound to the receptor 
and that may through the presence of the drug interfere 
with the assay. Fresh medium (25mls) containing 5% serum 
was added for 18 hours. The medium was collected and 
4mls added to each well containing CPAEs. ' After 3 days
the cells were trypsinized and counted electronically. 
Parallel cultures were set up containing 5% serum not 
conditioned.
RESULTS
The results for WIL and H125 are shown in Figure 14.
As can be seen conditioned medium from WIL cells stimulates 
the growth of CPAEs significantly with respect to cells 
incubated with medium not conditioned. This indicates 
the probable presence of one or more TAFs in the medium 
collected from WIL cells in culture. Proliferation of 
cells when incubated with medium from dexamethasone treated 
cells was significantly reduced compared to medium 
collected from untreated cells, indicating a possible 
reduction in secretion of mitogenic factors by WIL in 
the presence of dexamethasone. However, it is possible 
that the reduced in proliferation could be due to the 
presence of dexamethasone that has "leaked off" receptors 
into the medium and directly reduces the growth rate of 
CPAE. 7 WIL grows well as a xenograft in nude mice (see 
Animal Experiments) and thus must be able to induce tumour 
anigogenesis.
Conditioned medium from the cell line H125 does not 
signifigantly increase the proliferation of CPAEs compared 
to theAjnedium indicating a lack of mitogenic factors 
detectable by this system. The line H125 must secrete 
mitogenic factors since the cell line grows well in nude 
mice as a solid tumour. Furthermore, there is a 
significant drop in cell number in^cultures incubated 
with conditioned medium from H125 cells treated with
FIGURE 14 ASSAY OF SECRETED ANGIOGENIC FACTORS
BY 2 LUNG CELL LINES.
Angiogenesis was measured by- 
monitoring endothelial mitogenesis 
as stated in methods.
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dexamethasone compared to unconditioned medium in cultures 
of CPAEsJ This can be explained by the presence of 
dexamethasone in the medium that has been carried over 
following treatment with drug.
The reduction in proliferation seen with conditioned medium 
from WIL cells treated with dexamethasone may then be 
due to the presence of the drug and not totally attributable 
to a reduction in TAF secretion.
In conclusion this in vitro assay has two flaws. Firstly, 
the system does not detect all mitogenic factors. The 
two cell lines WIL and H125 must produce mitogenic factor 
since they both grow well in nude mice but only the former 
stimulates endothelial mitogenesis in vitro. Secondly, 
dexamethasone interferes with the assay and so an assay 
is needed that is unaffected by dexamethasone directly.
DISCUSSION
Tumour induced angiogenesis .is indicated by mitogenesis 
of pulmonary aortic endothelial cells (CPAE) by conditioned 
medium from, the cell lines A549 and WIL. The conditioned 
medium from these cells increased the rate of proliferation 
of cultures of CPAEs. Conditioned medium from cells 
pre-treated with dexamethasone caused a significantly 
reduced proliferation with respect to conditioned medium 
from untreated cells. However the results from experiments 
carried out with the cell line H125 indicate problems 
with these studies. Firstly there is evidence of 
dexamethasone carry-over; that is following treatment 
of the cells with dexamethasone there is incomplete removal 
of the drug before collecting conditioned medium. Secondly 
there does not seem to be any secretion of mitogenic 
factors secreted by as detected by this model. However 
the cell line H125 when injected into nude mice grows 
well as a tumour and thus must secrete angiogenic factors.
It is possible however that in vitro these factors are 
not secreted.
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It seems then that another experimental model may be needed 
to investigate angiogenesis. As stated earlier an assay 
exists that utilizes capillary endothelial cells (84)fc 
i ^  This assay has the added advantage that
it is these capillary endothelial cells which are the 
site of action of the tumour angiogenic factors. Also 
there is the possibility that migration of these 
endothelial cells is unaltered by glucocorticoid though 
this is unlikely. The key to this problem may be to 
get rid of the dexamethasone. This can be done in a 
number of ways. Firstly a more readily metabolized 
analogue of dexamethasone thus reducing the amount of 
glucocorticoid. Another approach is purification of 
the mitogenic factor or physical removal of it from the • 
conditioned medium in the latter case by charcoal stripping 
for example. The theoretical amount of dexamethasone 
that could be carried over can be easily calculated.
The amount of dexamethasone bound per cell is known from 
receptor assays and if we assume 100% carry-over the 
calculated dexamethasone concentration is 50nM which would 
almost certainly affect proliferation.
/;
v-
/
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4 . CARBOHYDRATES OF THE TUMOUR CELL SURFACE 
INTRODUCTION
Cancer is often described as "a social disease at the 
cellular level" and if this is so then many of the symptoms 
may show on the cell surface (91). It now appears that 
there is a correlation between carbohydrate changes and 
malignancy. The predominant glycoconjugates are 
glycoproteins containing 80% of all cell surface located 
carbohydrate. These carbohydrate units have an 
as^ymetrical distribution on the outer cell surface. The 
monosaccharides predominantly occurring in membrane 
glycoconjugatesqre the neutral sugars; mannose, galactose 
and fucose, the aminosugars; glucosamine and galactosamine 
and their acetylated derivatives N-acetylglucosamine and 
N-acetylgalactosamine including the negatively charged 
sialic acids (92). The oligosaccharides on the cell 
surface are placed into two groups depending on their 
amino-acid viz the N- and O-glycosidic types. The 
N-glycosidic can be further divided into the so called 
complex and simple type sugars (Figure 15). Both types 
contain a common core region and several branches of 
different types in complex type or mannose in simple type 
sugars. These sugar components on the cell surface are 
reported to be involved in specific cellular recognition 
(93). Processes associated with tumour growth and spread; 
loss of cell-cell adhesion, cell-cell interactions and the 
ability of cells to migrate, may be directly attributable 
to changes in the cell surface carbohydrates.
4.1 Surface Carbohydrates of Transformed Cells
The general observation to be discussed in this review is 
an alteration in the molecular weight of fucose containing 
glycopeptides derived from the proteolytic digestion of 
the cell surface (94). When analysed by gel filtration 
an overall increase in molecular weight was seen in tumour 
cells compared to their controls.
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Accompanying this there is a decrease in binding to the 
lectin Concdnavalin A .(Con A). Following treatment with 
neuraminidase, an enzyme specific for sialic acid residues, 
the differences between control and tumour glycopeptides 
we^eabolished in most cases.
Overall this can be interpreted as an increase in branching 
at the mannose units of complex obigosaccharides. This 
increased branching reduces or abolishes mannose specific 
binding to Con A and augments sialylation sites. In 
summary there is often the appearance of more large 
glycopeptides upon tumourigenic transformation.
4 . 2 Glycosyltransferases and Glycosidases
After the transfer of a high mannose precursor from a lipid 
intermediate to the nascent protein, protein carbohydrates 
are synthesized during a complex interplay of several 
glycosidases and glycosyltransferases (95). Cancer 
related changes must Isomewhere be generated along this 
route. As the increase in apparent molecular weight is 
mainly detected by an increase in the level of sialylation 
many attempts have been made to correlate the changes in 
tumour cells with changes in the activity or specificity 
of glycosyltransferases, notably of sialyl transferases. 
Warren et al (96) were the first to report on the increased 
amount of specific sialyltransferase in transformed as 
well as dividing cells. Elevated levels of 
sialyltransferases have subsequently been found in a range 
of transformed oslW y (97). However SV 40 transformed 
33T3 cells had a decreased sialyltransferase activity (98). 
Interestingly SV 40 transformed cells are often negative 
for the more highly sialylated membrane glycoproteins. 
Overall it can be said that there is an increase in 
sialyltransferase activity in surface molecules )of tumour 
cells.
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4.3 Changes in Individual Membrane Molecules
Although mainly studied in isolates of trypsin sensitive 
surface molecules, the ^ cpLycosylation change of transformed 
cells is a general phenomenon. Glycopeptide alterations 
associated with transformation of Balb/c cells have been 
observed in several individual proteins (99). Further/ 
the glycopeptides prepared from fibronectin of transformed 
cells contain more branches per core and a higher degree 
of sialylation without, however, affecting the adhesive 
properties (100). On the other hand no differences have hpen 
found in the glycopeptides derived from the transplantation 
alloantigens of normal and malignant cells (101).
4.4 Effects of Growth and Differentiation
Neoplastic cells often resemble undifferentiated, rapidly 
growing or embryonic cells in many phenotypic properties. 
Confluent non-growing, normal, cells contain more complex 
type surface glycopeptides and fewer oligo-mannosyl type 
glycopeptides than during active proliferation (102,103).
In addition to this difference in amount, the size and 
distribution of complex type glycopeptides can also be a 
function of proliferation state. A good example are 
hamster cells. Growing they have an enlarged quantity of 
the larger surface glycopeptides compared to the quiescent 
cultures (104).
Mouse (105) and human (106) teratocarcinoma cells contain 
a class of very large fucosyl glycopeptides with terminal 
galactose residues. These very large glycopeptides of 
embryonal carcinoma cells disappear following induction of 
differentiation, while the sialylated glycopeptides of the 
more common size range (107, 108) differ from adult tissue 
in the same manner as observed when comparing other pairs 
of normal and malignant cells. Differentiation of 
mammalian cells can be accompanied by structural changes 
in fucosylated surface carbohydrates (109).
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3An interesting case to note is that the ( H )-glucosamine 
labelled glycopeptide profile of gliomas can be made 
similar to normal glia by treatment of the tumour cells 
with dexamethasone which is a putative inducer of 
differentiation in this system. Treatment of trypsinates 
with neuraminidase abolishes this difference between 
tumour and normal cells implying that sialic acid is 
responsible (110).
4.5 Genetic Studies
It is known that cancer is caused at the molecular level 
by changes in the cellular DNA so changes in the surface 
carbohydrate sialylation may be related to changes in 
genomic rearrangement or gene expression. Transformation 
by oncogenic viruses usually appears as a single-step 
process by an en bloc transfer of the relevant information 
(111). Several studies with temperature sensitive mutants 
of transforming viruses has revealed that expression of 
the viral genome is required for the emergence of tumour 
associated carbohydrate changes (112). The entire viral 
genome need not however always be used in the investigation 
of transformation. De Leij et al (113) studied the 
carbohydrate changes following the transfection of rat 
kidney cells with restriction enzyme fragments of 
adenovirus 12 DNA. Transfection with a small left hand 
fragment resulted in immortalized and morphologically 
transformed but not tumourigenic cell lines whereas the 
entire El region was needed for the manifestation of a 
tumourigenic phenotype expressing characteristic changes 
in surface glycopeptides. Transfection of mouse 3T3 cells 
with DNA isolated from neuroblastoma cells resulted in 
tumourigenic clones expressing more highly branched 
glycopeptides (114). Also Collard and co-workers (115) 
transfected 3T3 cells with DNA from T24 bladder carcinoma 
and from HL-60 leukemia cells. Again a more highly 
branched structure was found and the DNA responsible for 
these changes was shown to be the ras oncogene, the 
continuous presence of which was required to maintain 
tumourigenic potential.
i
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This evidence suggests that tumour specific carbohydrate 
changes are caused by activation of the ras gene either 
directly or indirectly. This possibility is attractive 
for a number of reasons. Firstly, ras genes are analogous 
to the E1B region of adenovirus 12 in the malignant 
transformation of rat kidney cells. Moreover activation 
of ras oncogenes is increasingly observed in a wide range 
of tumours of different histogenic origins.
4.6 Biological Consequences of Altered Carbohydrate Changes
The dissemination of tumour cells into distant organs is a 
complex multi-step process involving release from the 
primary tumour, invasion into blood vessels or lymphatics, 
transport and survival of blood-bo^.rne tumour cells, 
extravasation from the capillaries and infiltration of 
the target tissue (116). Surface molecules are almost 
definitely involved in these processes. For instance 
Finne et al (117) reported that in poorly metastasvstw^j 
clones from mouse melanoma the amount of sialic acid in 
complex type carbohydrates was decreased with a concomitant 
increase in the amount of fucose residues while revertants 
of this phenotype were highly metastatic. On the other 
hand Steck et al were unable to detect alterations in 
surface glycoproteins of high and low metastatic cell 
lines of a rat mammary carcinoma (118). The answer to 
these conflicting reports may come from studies 
investigating single aspects of metastasis. One such 
study has been to examine the role of sialic acid in 
attachment to substrate glycoproteins by metastatic and 
non-metastatic murine tumours (119). The amount of 
neuraminidase accessible sialic acid was reduced on 
the surface of the non-metastatic clone compared to the 
highly metastic clone. Furthermore, this reduction in 
sialic acid was accompanied with a reduction in ability to 
attach to fibronectin and type IV collagen but no4 laminin, 
compared to the metastatic clone.
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Neuraminidase treatment of the metastatic cells enhanced 
their attachment to type IV collagen but not to laminin. 
Neuraminidase had no effect on the ability of the non­
metastatic cell to attach to any of the substrates.
In conclusion alterations in the carbohydrate may be 
responsible for directly,causing the appearance of 
malignancy associated properties which are essential for 
the progression of tumours.
METHODS
4 .1 Affinity Chromatography
Affinity chromatography is a powerful biochemical tool 
that utilises the inherent specificity of biological 
systems. A ligand is covalently attached usually by a 
linker molecule to an inert support, most often Sepharose. 
In this case the lectin Con A which has a specificity 
for mannose residues was used.
In this study cells were treated with dexamethasone
3
(26pM) for 3 days and then labelled with H-L-6 fucose 
(27 Ci mmol ^ ) for 16 hours in the presence of the drug.
The medium was then collected, the monolayers washed with 
PBS and 10 ug ml ^  of pronase in PBS added to' the .cells . 
After 30 minutes the cells were removed^and centrifuged:? 
Fresh pronase was added daily to the pronase removed 
components for 3 days. Samples were then centrifuged in 
a Beckman Microfuge for 10 minutes. The supernatant was 
decanted and used in studies in this form or frozen at 
-70°C till required.
About 2000cpm of glycopeptide was applied to a column of 
Con A Sepharose (0.9 x 15 cm) using 0.01M Tris pH 7.5 with 
0.1M NaCl as the buffer. The specific eluent was 0.2M 
OL-methylmannoside and 1% SDS was used to remove any 
• 'radioactivity. Fractions of 2 mis weref V-
collected for scintillation counting.
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Further characterisation of the glycopeptides was achieved 
by sequential digestion of the carbohydrate chains.
Labelled glycopeptides were treated as by Muramatsu et al 
(120) but with the following alterations. Neuraminidase 
(C.perfrinigens) was added to about 100 jal of sample, 
after the pH of the sample was reduced to 6.1 giving a 
final concentration of 0.05 U ml \ After 2 hours at 
37°C the samples were heated at 100°C for 5 minutes to 
stop any further activity. The reaction mixture was
allowed to cool and 0.28 U ml ^  of p-galactosidase (Jack 
bean) and 0.77 U ml of jB-N-acetylglucosaminidase (Jack 
bean) were added and the incubation allowed to continue at 
37°C for 40 hours. A small amount of toluene was added 
to stop bacterial contamination.
4 . 2 Gel Exclusion Chromatography
High performance liquid chromatography was used to 
investigate the molecular weights of the glycopeptides.1 
TSK SW columns were chosen. TSK G2000 SW has a working 
range of 70 to 5 kilodaltons while TSK G3000 SW operates 
between 150 and 15 kilodaltons. The columns were
calibrated with protein molecular weight standards. The
columns (0.75 x 30cm) were used with PBS as the buffer.
The flow rate was 0.2 ml min ^  and 0.2ml fractions were 
collected. A constant flow rate was maintained, and when 
detecting compounds spectrophotometrically an Altex flow 
cell coupled to a Hitachi spectrophotometer was 
incorporated into the system.
4 . 3 Lectin Mediated Agglutination
Cells were grown with or without dexamethasone for 3 days 
before harvesting for assay. This was done using EDTA 
(ImM) since trypsinization would remove cell surface 
glycoproteins. Cells were washed with EDTA for 30 seconds 
and then fresh EDTA was added for 15 minutes or till the 
cells detached.
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The cells were then washed with PBS twice and adjusted to 
_ 6 —I10 cells ml . Greater than 95% of the cells were 
judged to be viable by trypan blue exclusion. Lectin 
(0.1ml) was added to give final concentrations between 25 
to 0.39 jagml \  Agglutination was observed and ranked 
from ++++ to 0 by the author and an independant observor, 
++++ being maximal agglutination and 0 the level of 
agglutination observed in controls.
RESULTS
4 .1 Affinity Chromatography
Affinity chromatography . gave complex results.
The cell line WIL's glycopeptides had a decreased binding 
capacity for Con A Sepharose when treated with dexamethasone 
from 49% to 21% while the binding of glycopeptides from 
dexamethasone treated A549 was increased from 32% to 37%.
In the latter case the percentage increase is quite small 
and thus may not be significant. These changes could be 
due to an increase in sialylation in the case of WIL and a 
decrease in the case of A549. The percentage of 
glycopeptides from H125 bound to the affinity column was 
not altered when the cells were treated with dexamethasone. 
These results are summarised in Table 6.
Sequential treatment with the enzymes neuraminidase, 
p-galactosidase, and p-N-acetylglucosaminidase caused an 
increase in binding to the Con A Sepharose thus indicating 
the fucose labelled carbohydrate was of the complex type 
in all the cell lines investigated.
4.2 Gel Exclusion Chromatography
4.2.1 Proof for Pure Carbohydrate Content of Fucose 
Labelled Species
It had to be insured that the pronase digestion causee(the 
carbohydrate chain to be cleaved from the protein portion.
TABLE 6
CON
DEX
BINDING OF FUCOSYLATED GLYCOPEPTIDES 
TO IMMOBILISED CON-A SEPHAROSE (% BOUND)
WIL A549 H125
49 32 17
21 37 19
% bound is the percentage of radio activity 
released from the column following elution with 
•otmethyl mannoside (0.2M) and 1% SDS.
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To examine this a sample of the glycopeptide was added to 
chloroform:methanol (2:1; v/v) vortexed and the phases 
allowed to separate ‘1 • AnY carbohydrate attached to 
protein will be present in the chloroform phase. To 
lml of PBS 50 pi of sample was added and this mixed with 
chloroform. The two phases chloroform and methanol/PBS 
were added to scintillation fluid and counted. Typical 
results are shown in Table 7. As can be seen there are 
no counts above background in the organic phase.
ty
4.2.2 Gel Exclusion Chromatography Studies
Differences between the carbohydrates of normal and 
transformed cells can be monitored by gel exclusion 
chromatography (see introduction). As previously stated 
there is increased sialylation in transformed cells with 
respect to normal and this is manifested by an increase in 
molecular weight that this difference is abolished on 
treatment with neuraminidase.
Figure 16 shows the profiles of labelled glycopeptides of 
A549 generated from cells grown with or without 
dexamethasone. From the profiles it is obvious that there 
was no difference between the molecular weights of control 
and treated cell glycopeptides. Similar results were seen 
with WIL glycopeptides.
There is no evidence here to support dexamethasone treated 
cells having altered sugar components attached to cell 
surface components. It is unlikely that any changes in 
the carbohydrate werej missed due to a lack of column 
resolution, since resolution is already seen on the column 
and the working range of the column can handle the probable 
molecular weight range of the glycopeptides. Furthermore 
the possibility that it is due to incomplete protein 
removal is dismissed after the results from the previous 
section.
TABLE 7 AMOUNT OF (3H) FUCOSE LABELLED 
GLYCOPEPX4 ot' IN EACH PHASE
(3H) CPM PER PHASE 
CHLOROFORM PBS/METHANOL
A549 CON 37 1071
DEX 31 3187
WIL CON 26 1116
DEX 20 3331
A sample of (50^1) of labelled glycopeptides was added 
to 1ml of PBS. To this chloroform: methanol (2/l:v/v) 
was added and the mixture vortexed. After being 
allowed to separate each phase was counted for 
radioactivity.
FIGURE 16 EFFECT OF DEXAMETHASONE UPON ELUTION
PROFILES OF A54 9 CELL SURFACE PRONASE 
DIGESTS.
Aliquots of pronase digests were 
applied to a TSK-G2000SW column.
The flow rate was 0.5 ml min  ^and 
0.5 ml fractions were collected and 
counted in a scintillation counter.
FRACTION 
NO.
A549
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4.3 Agglutination of Cells by Plant Lectins
An easy and quick method of examining cell surface
- carbohydrates is to monitor lectin induced cell 
agglutination. The results of the cell agglutination 
experiments are shown in Table 8. Agglutination by Con A 
was inhibited by <x-methyl-mannoside and that by the wheat 
germ lectin WGA by N-D-glucosamine.
As can be seen dexamethasone had the greatest effect on 
WIL decreasing agglutination by WGA and Con A markedly. 
A549 was affected in a converse manner, dexamethasone 
irfcreasing Con A agglutination albeit only slightly. 
Agglutination by WGA was unaffected by dexamethasone 
treatment. The cell line H125 did not have changed 
agglutination characteristics when grown with the drug.
34.4 Effect of Dexamethasone Upon H Fucose Incorporation 
into Pronase Sensitive Fraction
Incubation of dexamethasone with A549 and WIL caused an
3increase m  the H fucose incorporation into the pronase 
sensitive fraction. However with H125 a significant 
decrease was observed. The results for A549 and H125 are 
shown in Table 9.
DISCUSSION
Dexamethasone was found to have different effects on the 
carbohydrates of the three cell lines WIL, A549 and H125. 
The results for the whole section are summarised in Table 
10. In the case of A549 the percentage of label that 
bound to Con A Sepharose was increased indicating a 
probable reduction in sialylation. Conversely with WIL 
there seems to be an increase in sialylation and with H125 
the percentage of label bound to the column was not 
altered.
TABLE 8 AGGLUTINATION OF H125, A549 AND WIL CELL LINES 
BY WHEAT GERM AND CONCANAVALIN A LECTINS
H125
A549
WIL
Lectin 
Concentration 
(pg ml”1)
25.0
12.5
6.25
3.13
1.56 
0.78 
0.39
0
25.0
12.5
6.25
3.13
1.56 
0.78 
0.39
0
25.0
12.5
6.25
3.13
1.56 
0.78 
0.39
0
W.C.A.
Dex Con
Con A 
Dex Con
+ + 
+ + 
+
+ + 
+ + 
+
+ ++ +  ++++ + + + +  +++
+ + ++ ++++ ++
+ + + + + 
+ + 
+
+ + 
+
+ + + 
+ + 
+
+ + + 
+ + + 
+ + + 
+
TABLE 9 EFFECT OF DEXAMETHASONE UPON (3H) FUCOSE
H125
A549
INCORPORATION INTO PRONASE SENSITIVE FRACTION
CPM X 10" 6  CELLS
DEX 8532 i 1988 *
CON 17377 - 5887
DEX 66366 - 13665 *
CON 19504 - 2960
Results are mean - s.d (n = 4)
3
Cells were labelled with ( H) fucose
5uCi ml- 1  for 16 hours. The pronase sensitive
fraction was prepared as in methods.
* Significant at the 5% level
TABLE 10 SUMMARY OF EFFECTS MEDIATED BY DEXAMETHASONE
RELATIVE TO CONTROLS ON CELL SURFACE
Con A
Agglutination
% -Glycopeptides 
Bound to Con A
(^H) Fucose 
Incorporation
A549 WIL H125
1 u  
1
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The data obtained from the agglutination studies agree 
with that from affinity chromatography experiments.
However no alterations in the size of the glycopeptides 
(aM?«s£- seen ma. gel exclusion chromatography. As
stated earlier it is unlikely that this is due to a lack 
of column resolution since three definite peaks are seen 
for example with A549 glycopeptides. A reasonable answer 
may be that the glycopeptides may be so large that the . 
differences in molecular weight between control and 
dexamethasone glycopeptides is negligible. The effect of 
dexamethasone on the amount of fucose labelled material in 
the pronase sensitive fraction is increased in the case of 
WIL and A549 but decreased in the case of H125. This 
agrees with other data in which the effect of the 
glucocorticoid was different between H125 and the other 
cell lines. These results are at odds with those obtained 
using lung tumour biopsy specimens and normal adjacent 
tissue in which it was found that in general the tumour 
had an increase in the amount of sialic acid, galactose, 
glucosamine and mannose (121). The increase in 
-malignancy associated carbohydrate changes in the case of 
WIL, which is the opposite of that seen in other parts of 
this thesis, may be explained by the fact that the cell 
lines normal function is secretory and the changes seen 
are related to this function. Overall the results from
investigations into tumour cell surface protein bound 
carbohydrates are in agreement with other findings in this 
thesis.
INTRODUCTION
5.1 Glycosaminoglycans
Glycosaminoglycans, GAGs, formerly known as 
mucopolysaccharides, are long, unbranched polysaccharide 
chains composed of repeating disaccharide units. They are 
known as GAGs because on of the two repeating units is 
always an amino-sugar. GAGs are highly negatively charged 
due to the presence of sulphate or carboxyl groups or both 
on many of the sugar residues (Figure 17). Seven groups 
of GAGs are known. They are chondroitin-4-sulphate, 
chondroitin-6 -sulphate, dermatan sulphate, heparan sulphate 
and keratan sulphate. The last member of the family is 
hyaluronic a.eid which is not sulphated (Table 11). 
Hyaluronic acid exists as a single chain of several 
thousand sugar residues in a regularly repeating sequence 
of disaccharide units (Figure 18). However hyaluronic 
acid is not typical of GAGs. Firstly, the others tend to 
contain a number of different disaccharide units arranged 
in a more complex manner. Secondly, the others have very 
much shorter chains, consisting of fewer than 300 sugar 
residues. Third, all of the other GAGs are covalently 
attached to protein to form proteoglycans. In lung mucus, 
GAGs, are involved in pulmonary defence. The viscous 
substance traps and dissolves pollutants and particles 
entrapped in the air passages. Ciliated epithelial cells 
move the entrapped species to the larynx where it is 
removed by swallowing
5.2 Modulation of Glycosaminocan Synthesis
A number of studies have investigated the factors which 
control lung GAG synthesis. Wu, Nolan and Hunter indicated 
the importance of both vitamin A and a collagen substratum 
for the expression of the fully differentiated properties 
of hamster tracheal epithelial cells (122). Electron 
micrographs found functional cilia and biochemical studies 
indicated that mucin was synthesised and secreted.
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Hyaluronic acid was synthesised in significant amounts 
accounting for 15% of high molecular weight label.
However the majority of radioactivity was associated with 
mucin glycoprotein i.e. not GAGs. Interestingly the 
production of mucin was related to kinetic parameters; 
confluent cultures produced more mucin per cell than did 
log phase cultures indicating a possible relationship 
between proliferation and differentiation. A similar 
study with rabbit tracheal epithelial cells found that 85% 
of secreted high molecular weight glucosamine labelled 
material was hyaluronic acid when cells were grown on 
collagen compared to exclusively hyaluronic acid with cells 
grown on plastic (123).
Only one report of synthesis of GAG•by pure cultures of 
normal human bronchial epithelial cells has been published. 
When grown in serum free medium retinoids were found to 
stimulate the secretion of hyaluronic acid as ^ell as 
altering the pattern of keratin synthesis (124). Thus it 
seems that normal human bronchial epithelial cells secrete 
purely hyaluronic acid and no mucin at least in this 
system. Retinoids stimulate the growth of these cells 
and so it seems that hyaluronic acid secretion is related 
to proliferation also although in a converse fashion to 
the previously mentioned hamster system (1 2 2 ). Jetten 
and Smits using rabbit tracheal epithelial cells found 
that the cells which could undergo squamous differentiation 
could be induced to differentiate into a mucin secreting 
cell by retinoic acid (125). In this system at least 
there seems to exist a precursor cell whose pathway of 
differentiation can be controlled.
METHODS
f 2Cells Are in^oculated in either 25cm flasks or 24 well 
plates and dexamethasone (26 jiM) was added for 3 days 
during the log phase of growth. Parallel cultures with no 
dexamethasone were set up as controls.
43.
-1 3Cells were labelled with 10 uCi ml of 6 - H (n)
-1 2 glucosamine (29Ci mmol ) for 24 hours. For 25cm
flasks 2ml and for 24 well plates 0.3ml of medium was
added. At the end of labelling period the medium was
2
collected and the monolayers washed with 1ml (25cm 
flasks) or 0.1ml (24 well plates) of medium the samples 
pooled and lyophilized. Prior to application to a TSK 
G3000 SW column the samples were resuspended in PBS with 
2% mercaptoethanol (v/v). The column was run at a flow 
rate of 0.5mlmin^ using PBS with 5mM dithiothreitol (DTT) 
as the eluent. Radioactivity in the void volume (Vo) was 
pooled and lyophilized. Experiments were carried out to 
identify the class or classes of GAGs present. This was 
done in three ways; enzymatically, chemically and by 
ion-exchange chromatography. To identify hyaluronic acid 
the enzyme hyaluronidase ( bovine testes ) was added
to the samples at lOUml ^ in PBS adjusted to pH6.0 with 0.1M 
citric acid and incubated at if*C for 16 hours. After 
digestion, samples were applied to the TSK G3000 column 
and elution profiles gathered. Samples were also treated 
with chondroitinase AC 0.3Uml^ for 5 hours at 3f*C in 
50mM acetate buffer (pH 5.5) and elution profiles gathered. 
To test for the presence of heparin aliquots were incubated 
for 2 hours at 37°C with 0.75M NaNO* and 2. 5M HC1. The 
incubation was terminated with the addiion of 0.1M ammonium 
sulphamate (126). Again elution profiles were gathered. 
Prior to ion-exchange chromatography samples were desalted 
on Sepl-iadex G-10. The desalted samples were applied to a 
TSK DEAE 5PW column (0.75 x 7.9 cm) equilibrated with 
50mM acetate buffer (pH 5.5) containing 0.15M NaCl.
Attached species were removed either stepwise or with a 
linear gradient of NaCl (0.1-0.7M). The column was run 
at 0.5 mlmin ^  and 2ml fractions were collected. The 
concentration of NaCl in each fraction was determined by 
conductivity using a standard curve.
RESULTS
5.1 WIL
5.1.1 Types of GAGs Secreted
3
High molecular weight H-glucosamine labelled molecules 
5
( > 5 x 10 daltons) were secreted into the medium by WIL 
cultures in considerable amounts. High molecular weight 
material is that found in Vo fractions. There appears to 
be reproducible differences , in elution profiles
between dexamethasone treated cultures and controls with 
respect to the void volumes (Figures 19 and 20).
Conditioned medium from dexamethasone treated cells appeared 
to have two peaks when elution profiles were examined. 
Furthermore there weye.considerable alterations in the 
labelled species upon the column, between Vo and Vt, but 
these changes were not further investigated. Pooled Vo 
fractions were treated with hyaluronidase which is quite 
'specific for hyaluronic acid and this caused the whole 
label to appear in fractions at Vt with both control and 
dexamethasone treated samples. A small fraction of the 
sample stays within the Vo fractions but this accounts for 
less than 0 .1 % of all radioactivity applied to the column 
(Figure 21). This radioactivity is digested hyaluronic 
acid. This indicates that the bulk of the high molecular 
weight label is hyaluronic acid. However further work is 
needed to ensure that this is the case. Contaminating 
enzymes in the hyaluronidase preparation may degrade non- 
hyaluronic acid material. Further hyaluronidase is not 
totally specific for hyaluronic acid also digesting 
chondroitin sulphates. To gain further evidence for the 
presence of hyaluronic acid samples were treated with 
chondroitinase AC which degrades hyaluronic acid but not 
to the same extent as the chondroitins. As can be seen 
degradation of samples does occur but not to the same 
extent as is seen with hyaluronidase (Figure 22). Samples 
treated with nitrous acids did not have altered elution 
profiles (results not shown).
FIGURE 19 ELUTION PROFILE OF CONDITIONED
MEDIUM FROM CONTROL CULTURES 
OF WIL
Plateau phase WIL cells were incubated 
with 2mls of 10 pCi ml 1 of (3h) 
glucosamine for 24 hours and the 
conditioned medium collected.
The medium was lyophilized and then 
resuspended in PBS containing 2% 
mercaptoethanol. Aliquots were 
applied to a TSK G3000SW column and 
elution carried out with PBS 
containing 5% DTT and 0.02% Na 
a^ .;ide at 0.5ml min~l. Fractions 
of 0.5ml were collected.
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FIGURE 20 ELUTION PROFILE OF CONDITIONED
MEDIUM FROM DEXAMETHASONE TREATED 
CULTURES OF WIL
Plateau phase WIL cells were pre­
treated with dexamethasone (26 jiM) 
for 3 days prior to incubation with 
2mls of 10 jiCi ml of (^H) 
glucosamine for 24 hours and then 
medium collected. The medium was 
lyophilized and then resuspended in 
PBS containing 2% mercapto ethanol. 
Aliquots were applied to a TSK G3000SW 
column and elution carried out with 
PBS containing 5% DTT and 0.02%
Na azide at 0.05 ml min-l.
Fractions of 0.5ml were collected.
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FIGURE 21 HYALURONIDASE TREATMENT OF V G 
RADIOACTIVE MATERIAL.
Aliguots of Vo material were treated 
with 10 U ml“l of hyaluronidase for 
16 hours at 37QC. Samples were then 
applied to a TSK-G3000SW column and 
elution profiles gathered. The flow 
rate was C .5ml min~l and 0.5ml 
fractions gathered.
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FIGURE 22 CHONDROITINASE AC TREATMENT OF Vo
RADIOACTIVE MATERIAL.
Aliquots of Vo material were treated 
with 0.3 U ml~l of chondroitinase 
AC for 5 hours at 3 7QC. Samples
were then applied to a TSK G3000SW 
column and elution profiles gathered. 
The flow rate was 0.5ml min~l and 
0.5ml fractions gathered.
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Hyaluronic acid has a characteristic elution profile 
when using DEAE ion-exchange chromatography due to the 
negative charge of the GAGs and so bind to the positive
t
charge of the column packing material. All counts 
attached to the column when equilibrated with 0.15M NaCl. 
When eluted with NaCl a single peak coming off at a 
NaCl concentration of 0.25M was seen suggesting that 
hyaluronic acid is the only species present (Figure 23). 
Hyaluronic acid is known to elute at this salt 
concentration (124).
It is clear that hyaluronic acid is secreted by the 
adenocarcinoma WIL in vitro. No differences were seen 
between control cultures or those incubated with 
dexamethasone with respect to class of GAG released into 
the medium.
5.1.2 Modulation of Hayluronic Acid Secretion in WIL by 
Dexamethasone
To ascertain if dexamethasone modulated the secretion of 
hyaluronic acid, cells were grown In 24 well plates and 
material isolated as in methods. The amount of radio­
activity that stayed in within the Vo fractions was taken
to be hyaluronic acid and the results expressed as Vo 
—  6cpm 10 _ cells. When grown with dexamethasone (26 jiM)
WIL cells had significantly reduced hyaluronic acid 
secretion (Table 12). The control levels found for this 
cell line are very similar to those obtained for hamster 
tracheal epithelial cells (1 2 2 ).
FIGURE 23 ION EXCHANGE CHROMATOGRAPHY OF V o 
MATERIAL.
Desalted V o material was applied to 
a DEAE column equilibrated with 
acetate buffer PH 5.5 (50 mM) 
containing 0.1m NaCL. Attached 
species were removed by elution with 
a linear gradient of NaCl. The flow 
rate was 0.5ml min-l and 0.5ml 
fractions collected.
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TABLE 12 HYALURONIC ACID SECRETION BY WIL AND H125 AND
WIL
H125
ITS MODULATION BY DEXAMETHASONE (26pM)
CPM X10~ 6 CELLS
CON DEX
9161 - 100 6797 i 387 *
8992 - 1087 14465 - 3157 *
* Significant at the 5% level.
mean - standard deviation (n = 3).
Hyaluronic acid is counts in Vo fractions on 
TSK G3000SW.
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5.2 H125
5.2.1 Types of GAGs Secreted
As with WIL cells, H125 secreted high molecular weight 
compounds into the medium. No differences were seen in 
the profiles of material from dexamethasone treated or 
control cells. Utilizing the same approach as in 
section 5.1.1, it was found that the only class of GAG 
secreted was hyaluronic acid (results not shown).
5.2.2 Modulation of Hyaluronic Secretion in H125 by 
Dexamethasone
Dexamethasone significantly increased the amount of 
hyaluronic acid by H125 (Table 12).
DISCUSSION
The human lung adenocarcinoma cell lines WIL and H125 
secrete hyaluronic acid in vitro. This was ascertained 
by a variety of biochemical techniques. Although the 
marker of differentiation in these secretory cells is 
mucin neither WIL or H125 synthesised either protein 
bound GAGs or mucin glycoprotein. This may be explained 
by the fact tht the addition of a substratum is needed
i V
for full expression of the differentiated phenotype as 
was seen in previous reports (121, 122, 123). It is 
possible that the secretion of hyaluronic acid is 
indicative of an undifferentiated phenotype and if this 
is true then the action of dexamethasone upon WIL and 
H125 would agree with other results in this thesis. 
Dexamethasone reduces malignancy associates parameters 
in WIL while increasing these in H125. If hyaluronic 
acid is a marker of de-differentiation then the results 
observed would agree with the hypothesis that 
dexamethasone induces differentiation in WIL but 
malignancy in H125.
As stated earlier dexamethasone reduces hyaluronic acid 
secretion in WIL while in H125 it is increased. No 
mucin synthesis was seen because of the lack of a 
substratum either added chemically or by the presence of 
mesenchyme. Thus it may be that although dexamethasone 
is essential, in this system, for differentiation it is 
not sufficient.
Another interesting result from these experiments is that 
the control of hyaluronic acid in these two cell lines 
is intrinsically linked to the level of proliferation.
In the presence of dexamethasone the growth rate of WIL 
is decreased while that of H125 is increased.
6 . PULMONARY SURFACTANT
49.
INTRODUCTION 
Pulmonary Surfactant
The synthesis of pulmonary surfactant is essential for 
the normal functioning of the lungs and its production 
and presence is characteristic of mature lung.
The material reduces surface tension within alveoli and 
thereby prevents alveolar collapse and transduction.
Surfactant composition has been studied and the components 
are well documented. Chemical analyses indicate that 
it is a complex mixture of phospholipids and proteins.
The component in largest supply is dipalmitoylphosphatidyl 
choline (DPPC). Together with small amounts of other 
anenoic phosphatidycholines it comprises from 41 to 58% 
of total surfactant lipid (128, 129). it is likely this 
DPPC is responsible for the surface tension lowering 
properties of surfactant. Monoenic phosphatidylcholines 
account for approximately 11 to 29% of total surfactant 
lipid and of the remaining phospholipids 
phosphatidylethanolamine (PE) teads at 5 to 10%. '■ 
Phosphatidylglycerol (PG) may be present in amounts of 
up to 1 0 % and when full saturated may even contribute 
to surface tension lowering ability. Neutral lipids 
comprise 5 to 13% of total surfactant lipid.
Another minor (less than 10%) but important component 
of surfactant is non serum protein. The surface associated 
glycoproteins (SAG) are lung specific proteins of molecular 
weight 30 to 40 kilo daltons (Kd) (130). These subunits 
are cross-linked by means of di-sulfide bonds to form 
a high molecular weight aggregate of greater than 400 
Kd (131). Using antibodies against SAG s the relationship 
of phospholipid production with the protein component 
of surfactant were investigated (132). The results indicated 
that synthesis and secretion of these glycoproteins involved 
the same cytoplasmic organelles for synthesis, packing, 
storage and exocytosis of surfactant phospholipids.
However, it did not appear that the phospholipids and
SAG were stored together within the cells responsible 
for producing surfactant type II pneumocytes.. A typical 
alveolar type II cell will, if examined with electron
microscopy (E.M.), have distinct organelles called lamellar 
bodies which seem to act as stores of surfactant (133).
The lamellar bodies are secreted into the sub-phase of 
the alveoli where they,are arranged to form surfactant.
f
Although the chemical and physical composition of 
surfactant is well understood, the mechanisms controlling 
production are still under investigation. Much 
information has come from fetal tissue due to the -fact, 
that premature children often have problems in breathing 
due to a lack of pulmonary surfactant. Avery led a large 
number of investigators in discovering that DPCC production 
and low surface tension of extracts were promoted by 
glucocorticoids (134). The exact mechanism by which 
the glucocorticoids exert their action has been the subject 
of much investigation $nd although much is known more 
work is needed.
Using the human pulmonary alveolar carcinoma derived 
cell line A549 it was found that it synthesized and 
secreted saturated phosphatidylcholine (135). v 
Qortisol significantly stimulated ( H ) choline 
incorporation into the phosphoj lipid by 26%. The steroid 
also increased the amount of saturated phosphatidylcholine 
that could be released by acetylcholine, carbachol and 
isoprotorenol (isoprenaline), but had no effect on 
secretion itself. However, the same author found that 
glucocorticoids incubated with fetal human alveolar type 
II pneumocyies showed only minimal response on surfactant 
production unless other lung cells (endothelial and 
mesenchymal) were present (136, 137, 138).
Serum free medium collected after incubation of fetal 
human lung fibroblasts with cortisol contained a factor 
that caused accelerated lung maturation when injected 
into fetal rats (139). This fibroblast-pneumocyte factor
(FPF) had a molecular weight of between 5 and 7Kd>was
heat stable, dialyzable' and a polypeptide. Furthermore,
3 •FPF increased ( H ) choline incorporation into disaturated
phosphatidylcholine by 56%. More recently it has been
shown that FPF also increase formation of
phosphatidylglycerol from labelled glycerol and palmitate.
3As well as observing an increase m  i H.) choline 
incorporation into disaturated phosphatidylcholine a 
concomitant and equal increase is seen of the 
radioactive tracer into phosphatidylcholine (140).
Incubation with onoclonal antibodies raised against FPF 
cortisol stimulated synthesis of saturated
phosphatidylcholine in fetal rat lung organotypic cultures. 
Furthermore, injection of the antibody into embryonic 
chicks delayed lung maturation (141).
Although there is a role for epithelia-mesenchymal 
interactions in surfactant production and its 
stimulation by glucocorticoid there is also evidence of 
a direct action of glucocorticoids upon type II 
pneumocytes. Maniscaleo and Shapiro (142) found that 
dexamethasone increased the number of B adrenergic 
receptors by twofold in fetal rat lung explants and the 
authors suggest, but have no evidence, that it is in type 
II cells on which this increase occurs. Using Wl-38 
human fetal lung fibroblasts and its SV 40 transformed 
counterparts VA2 , along with VA4 , SV 40 transformed 
Wl-26. Hydrocortisone was observed to cause an increase 
in receptor concentration in a dose dependant manner 
(143). Since p agonists cause release of saturated 
phosphatidylcholine and cortisol augments this effect 
on the cell line A549, it is possible that there is a 
physiological role for glucocorticoids directly on type 
II cells.
Although glucocorticoids are obviously important in 
controlling synthesis of surfactant there are other 
agents which can affect its production and are probably 
of physiological importance. The "second messenger"
cyclic adenosine monophosphate (cAMP) along with 
phosphodiesterase inhibitors was7 found to increase (methyl- 
14q choline) incorporation into both saturated and 
unsaturated phosphatidylcholine in fetal rabbit type II 
alveolar cells (144). Nites and Matarski (145) have 
demonstrated that cAMP analogues increased total 
phosphatidylcholine and disaturated phosphatidylcholine 
in A549 cells.
Myo-inositol potentiated the dexamethasone and thyroxine 
induced increase in saturated phosphatidylcholine in fetal 
rabbit lung (146) and insulin reduced glucose incorporation 
into phosphatidylcholine in fetal rat lungs (147).
Methods
The measurement of synthesis of surfactant was carried
out utilizing the technique of Smith (135). Cells were
-4 _ 2
plated at a concentration of 5x10 cm and after growing 
to confluence the medium was replaced with serum free 
medium. The cells were incubated with serum free medium 
containing 0.26 pm dexamethasone for 48 hours in the case 
of treated cells. Parallel cultures as controls were
also set up. The cells were then labelled with O.lpCi
-1 3U -1
ml of h methyl choline chloride (80 Ci mmol ) for
24 hours.
6 .1 Cellular Surfactant Synthesis
To examine phosphatidylcholine biosynthesis cells in 
-2
25cm flasks were incubated with label as stated. The 
medium was removed and replaced with 5ml of methanol.
The. cells were scraped from the flask and 5ml of lOOmM 
KC1 with 10ml of chloroform added to the suspension.
At this stage 0.2mg of dipalmitoylphosphatidylcholine 
and l.Omg of phosphatidylcholine added as "cold" carriers. 
To correct for recovery 14c dipalmitoylphosphatidylcholine
(approximately 2000 cpm) was added. The extracts were 
shaken, allowed to separate and the organic phase was 
removed and evaporated to dryness in a vortex evaporator 
(Bu chler).
Disaturated phosphatidylcholine was isolated by column 
chromatography on neutral alumina (148). Evaporated 
chlbroform extracts were treated with 3.1mg of osmium 
tetroxide in 0.5ml of carbon tetrachloride for 15 minutes. 
Samples were evaporated to dryness and redissolved in 
0.5ml of chloroform-methanol 20:1 (v/v) and applied to 
isolation columns. These consisted of lg of neutral 
alumina on a plug of glass wool in a 9 incK Pasteur 
pipette. The neutral lipids; which did not bind to the 
columnjwere eluted with 2 0 ml of chloroform-methanol 2 0 : 1  
(v/v). The disaturated diphosphatidylcholine is then 
eluted with 10ml chloroform-methanol-7M ammonia 70:30:2 
(v/v). The eluted disaturated phosphatidylcholine in 
eluent was evaporated, scintillant added and counted in 
a double channel counter (Packard).
6 .2 Secreted Surfactant
Measurement of secreted surfactant was similar to that
of cellular surfactant synthesis. After the labelling
period the medium was decanted and the cultures washed
3 times with 5ml of PBS. Cells were incubated with 3ml
—  6
of serum free medium containing 1 0  isoproteronol for 
15 minutes. Dexamethasone acts directly on alveolar 
cells to increase B adrenergic receptor number and B 
agonists stimulate surfactant release (135, 143). The 
media was collected, spun down to remove any contaminating 
cells and then 3ml of methanol added. The mixture was 
vortexed and 6 ml of chloroform added and the sample 
revortexed for 30 seconds. The sample was spun down 
at 2 0 0 0 , (4 \ %) for 1 0  minutes , the aqueous phase removed
and the chloroform layer evaporated to dryness as before. 
All the remaining purification steps were as for cellular 
investigation studies (6 .2 ).
54.
RESULTS
Effect of Dexamethasone on Surfactant Synthesis
Dexamethasone was found to increase the effect of 
isoproteronol on disaturated phosphatidylcholine release 
in A549 cells. A significant increase of about 2 fold 
was seen. However, with the adenocarcinoma WIL there 
was a decrease.
Dexamethasone was found to significantly increase 
'disaturated phosphatidylcholine in monolayers of both 
cell lines. The increase was about twofold in each case 
(Figure 24).
DISCUSSION
Dexamethasone increased cellular synthesis and secreted 
surfactant in A549 cells. These'results are similar 
to those previously reported. It appears then that 
dexamethasone can increase differentiation in this alveolar 
carcinoma cell line. Interestingly, it was reported 
that, the amount of surfactant synthesised was inversely 
related to the rate of growth ie the state of proliferation 
(135). However, the fact that the cell line WIL 
synthesises and secretes surfactant is unusual since it 
is thought to be an adenocarcinoma. The results can 
be rationalized. Firstly, the increase in disaturated 
phosphatidylcholine in the cell membrane may be a general 
membrane effect since these compounds are a common 
component of membranes and thus dexamethasone modulation 
of its presence could be indicative of a change in the 
membrane. This would not however explain the presence 
of secreted phospholipid. It is possible that WIL is 
a pluripotent (at least bipotent) precursor or stem cell 
that can have the properties of a surfactant and mucus 
secreting cell. This is not the first time that this 
has been proposed (149).
FIGURE 24 EFFECT OF DEXAMETHASONE UPON
PULMONARY SURFACTANT SYNTHESIS AND 
SECRETION..
Pulmonary surfactant was measured as 
in methods.
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The fact that dexamethasone does not increase secretion 
of disaturated phosphatidylcholine may be due to the fact 
that there i£ little surfactant secreted initially and 
the levels are near those that the assay can measure.
56.
7. ANIMAL EXPERIMENTS 
INTRODUCTION
The ability to change the phenotype of carcinoma cells in 
vitro has been well documented but if differentiation 
inducing agents are to be of any use in chemotherapy then 
they must act in vivo. An agent may be very promising in 
vitro but when examined in vivo exhibit little activity.
This can be due to a number of reasons; e.g. metabolism, 
distribution, penetration, or the dose needed is not 
pharmacologically attainable. The in vivo response in 
relation to that in vitro is interesting also as a scientific 
exercise.
Animal tumours grow readily in rats, mice and other animals 
but if human tumours are to be grown in vivo the problem of 
tumour rejection has to be overcome. Human tumours cannot 
be grown in animals unless the animal’s immune system is 
removed or greatly suppressed.
Animal (studies) are now available for the investigation 
of chemotherapy of human tumours. In 1969 the growth of 
human tumours (xenografts) was first reported (150). The 
serially transplanted tumours very often had pathology 
similar to the initial tumour although xenografts rarely 
exhibit metastases (151). Chromosomal studies indicatecj 
only human genetic material in the transplanted tumours 
(152). In many cases the xenograft tumour response to 
chemotherapy correlates with patient response. This was 
the case of bronchialcorcinoma xenografts (153).
Xenografts have also been used in investigating the 
activity of interferon a differentiating agent (154).
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Methods
7.1 Mice
MF^l (nu/nu) were used as immuno-incompetent animals.
The mice lack T-cells. These mice were kept under sterile 
conditions and had sterile food and water ad libitum. 
Animals were used between 6 and 9 weeks of age.
AKR mice were used for the growth of the murine ROS tumour.
7.2 Tumour
All tumours were passaged and grown as follows
Dissected tumours were cut up into pieces of 3 x 3  mm and 
placed sub-cutaneously (s.c.) in the animals. The tumours 
were used for experiments about 2 weeks post-passage.
The tumours WIL and H125 were obtained from cells grown 
in vitro and injected into mice. The ROS tumour was 
derived as reported previously (155).
Tumour diameters were converted to approximate tumour 
volume by the formula
3
Tumour Volume = (mean tumour diameters) x TT
6
Tumours were excised, treated and controls, placed in 
formol saline and processed for histology.
To examine for the effect of dexamethasone upon 
tumo,^rigen * city confluent cultures of WIL cells were 
incubated with or without dexamethasone (26 jiM) for 3 
days, the medium aspirated and the monolayers washed twice 
with PBS/EDTA and then trypsinised. The trypsinised
cells were then washed with PBS and suspended in PBS at a
_6 — 
concentration of 5 x 10 cells ml
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Cells were in^oculated into nude mice (1 x 10 cells in 
0 . 2  ml) subcutaneously and at various times the mice were 
examined for palpable tumours.
Drug was injected intra-peritoneatally (I.P.).
RESULTS
7.1 Effect of Dexamethasone Upon Tumour Growth
7.1.1 Effect of Dexamethasone Upon ROS Tumour Growth
Mice carrying the Ridgeway Osteogenic Sarcoma (ROS) 
tumour were injected with either dexamethasone or PBS.
Two regimes were used with their corresponding controls : 
day 0  was the date of the first injection.
la. Treated on day 0 with 0.005 ml of PBS g ^
lb. Treated on day 0 with lOOpg of dexamethasone g ^
2a. Treated on days 0-4 with 0.005 ml of PBS g ^
2b. Treated on days 0-4 with 20pg of dexamethasone g ^
Results are shown in Figure 25. Dexamethasone given as 
5 doses I.P. caused a significant reduction in the size of 
the tumour compard to the controls. Controls over a 10 
day period had a 4-fold increase in tumour size to 5g 
while the dexamethasone treated tumours to 2.9g. From 
this experiment it is clear that the glucocorticoid caused 
a significant decrease in the growth rate of ROS tumour in 
AKR mice.
7.2.1 Effect of Dexamethasone Upon WIL Xenograft Growth
Nude mice were implanted with WIL xenograft. After 
approximately two weeks most tumours were of a size that 
could be used for experiments. Dexamethasone (20 jag 
g- )^ was injected I.P. 10 times over 12 days. Tumour 
size was measured by callipers as stated in methods.
FIGURE 2 5 EFFECT OF DEXAMETHASONE UPON ROS
TUMOUR GROWTH.
Dexamethasone (20^g g-1) was 
administered I.P. into AKR mice bearing 
ROS tumour. After 10 days tumours 
were excised and weighed.
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After 12 days tumours were either excised and sent for 
histology or injected with PBS to investigate reversibility 
of growth inhibition or dexamethasone was given to see if 
tumour regression could be achieved.
Response i©-4uimoux-^ith—or—-w-it-hou£ dexamethasone over the 
first 12 days is shown in Figure 26. Inhibition of 
tumour growth was seen after 2 days of treatment. At 
the end of the regime mean control tumour volume was over 
4-fold the volume of the tumours at the initiation of the 
experiment. Dexamethasone treated tumours had very 
similar volumes of those at the initiation of the 
experiment i.e. dexamethasone totally inhibited the growth 
of WIL xenograft. Furthermore, from 9 days onwards the 
mean tumour volume fell and was still falling at day 1 2 . 
Thus at this point there is evidence of tumour regression. 
Experiments were carried out to see if tumour regression 
could be attained by maintaining the regime beyond 1 2  days. 
However, it was found that there was no loss in tumour size 
when the regime was extended (results not shown).
The effect of dexamethasone upon WIL xenograft was found 
to be reversible. After regime of ten injections
over twelve days the tumours were measured at regular 
intervals in the absence of further treatment with 
dexamethasone. All tumours previously treated with 
dexamethasone resumed growth with doubling times very 
similar to untreated control tumours. Table 13 shows the 
doubling times of tumours .treated and controls. The 
doubling times represent the time needed for a doubling 
of tumour volume once the tumours started regrowing.
No significant difference was found.
7.2.2 Effect of Dexamethasone on Tumorigenecity of WIL
. 5
Mice were in^oculated with 5 x 10 WIL cells with or 
without dexamethasone at 26jjM for 3 days. The results 
are shown in Figure 27.
TABLE 13 DOUBLING TIME OF WIL XENOGRAFTS AFTER DEX 
WITHDRAWAL
1st Doubling 2nd Doubling Control
(No DX)
Mean 17.4 7.0 8 . 6
S.E. - 3.6 * 1.65 - 0.5
n 5 5 5
FIGURE 26 EFFECT OF DEXAMETHASONE UPON THE 
GROWTH OF WIL IN VIVO.
Xenogra-fb bearing nude mice were 
given dexamethasone ( 2 0  g g~l) on 1 0  
days out of 12. Tumour volume was
measured by callipers.
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FIGURE 2 7 EFFECT OF DEXAMETHASONE ON 
TUMORIGENICITY OF WIL.
Confluent cultures of WIL were 
incubated with or without 
dexamethasone (26pM ) for 3 days.
ia . . .
Cells (10 ) were then injected into 
mice (S.C.). Mice were inspected 
daily for palpable tumours. Six 
mice are in each group.
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J'
Dexamethasone increase clothe tumorigenecity of WIL cells in 
nude mice with respect to control cells. ' At 8  days post- 
iiT>oculation 50% of mice bearing dexamethasone treated 
cells have palpable tumours compared to 15% with control 
cells. At 15 days 100% of mice innoculated with 
dexamethasone treated WIL cells compared to 80% with 
untreated WIL cells. It appears that initially 
dexamethasone treated WIL cells are more tumorigenic than 
untreated cells.
7.4 Effect of Dexamethasone Upon H125 Tumour Growth
Nude mice bering H125 tumour were treated with 
dexamethasone or PBS in exactly the same way as WIL 
xenograft (Section 7.2.1). In this case dexamethasone 
was found to have no effect on the growth of H125 when 
compared to controls (Figure 28).
7.5 Histology of Treated Xenografts
Tumours were excised, fixed in formalin and mounted for 
staining. Control and dexamethasone treated tumours 
stained with H and E are shown in Figures 29a and 29b.
As can be seen there is much more central necrosis in 
the dexamethasone treated tumours. In Figure 29a there 
is a much deeper band of viable cells compared to the 
dexamethasone treated tumour 29b.
At higher magnification mitotic cells (M) can be seen in 
the centre of the dexamethasone treated WIL tumour. 
However, there is also much evidence of vacuolation of 
cells. On the-whole there are fewer mitotic cells in 
dexamethasone treated tumours 30. g-
DISCUSSION
The growth of the ROS tumour was significantly reduced by 
dexamethasone although at higher doses toxicity was 
observed.
Fig 29b
x4 (H&E)
x40 (H&E)
FIGURE 28 EFFECT OF DEXAMETHASONE UPON THE 
GROWTH OF H125 IN VIVO.
Xenograft bearing nude mice were 
given dexamethasone (2Qpg g-1) on 
10 days out of 12. Tumour volume 
was measured by callipers.
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Studies with the lung xenografts show that the in vivo 
response to dexamethasone correlated with that in vitro in 
/the case of the lung xenografts. In vitro the cell line 
WIL had lowered growth rate (at normal passage densities), 
terminal cell density, clonogenicity in agar, PA levels,in 
the presence of dexamethasone. Clonogenicity as a 
monolayer was increased :>y dexamethasone. The growth of 
the xenograft derived from the cell line was totally 
arrested by dexamethasone.
The growth of the tumour H125 in nude mice was unaltered
t
by dexamethasone. In vitro the cell line had an increased 
growth rate (at regular passage densities) terminal cell 
density and PA activity in the presence of dexamethasone. 
Clonogenicity in agar was reduced but monolayer cloning 
was unaffected by the glucocorticoid. It appears then 
that the response (or lack of it) to dexamethasone in 
vitro correlates with that in vivo.
These results are in agreement and expand upon the study 
using a murine mammary carcinoma where reduction in in 
vivo PA content of tumours was directly related to 
reduction in in vivo growth rate (62 ). in our study 
with the cell line WIL, in vitro PA reduction correlated 
with growth rate reduction in vitro and inhibition of 
xenograft growth. The cell line H125 had a raised PA 
content and growth rate in vitro while the growth rate 
in vivo was unaffected by dexamethasone. The mode of 
action of dexamethasone's inhibition of growth of WIL 
in vivo appears to be due to vascular collapse. Histology 
of the excised WIL tumours showed that in treated tumours ■ 
there was only a thin layer of viable cells on the outside 
of the xenograft with central necrosis. With control 
tumours a deeper band of viable cells is seen with much 
less central necrosis. If the growth inhibition was due 
to a direct cytotoxic action then the outer layers would 
not be viable as they are the first cells to "see" the 
drug.
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The vascular collapse was not due to a direct effect on the 
growing endothelial cells in the vasculature since the 
growth of H125 is unaffected by dexamethasone. Thus in 
the case of WIL dexamethasone seems to abolish growth by 
inhibiting angiogenesis. More conclusive evidence could 
come from investigating angiogenic factors by the cell 
lines WIL and H125 or by directly examining the vasculature 
of the tumours in vivo as done by Braunschwieger (156).
Dexamethasone was found to increase the .±=0 ^ 0 ^^ -b=*Kc of 
WIL cells in nude mic^ albeit transiently. This result 
is not in line with the observation that dexamethasone 
reduces malignancy associated'parameters. Also a 
reduction of tumorigenecity would be expected to accompany 
the reduction in growth rate. As a chemotherapeutic 
agent an increase in tumorigenecity would not be beneficial. 
There have been reports however that more differentiated 
cells are more tumorigenic (157). This anomaly can be 
explained by the fact that the increase in tumorigenecity 
is due to an increase in adhesiveness in the WIL cells 
thus aiding tumour take. 'If this is the case then what 
is being observed is actually an increase in a
characteristic that may reduce tumour spread.
»
There are two possible reasons for, the transient nature 
of dexamethasone's increase in tumorigenecity in WIL cells. 
Firstly, the action of dexamethasone in vitro is reversible 
and so, after a certain time, any difference between 
treated and control cells will disappear. Secondly, 
the increase in tumour take may be due to the presence 
of dexamethasone that has dissociated from the receptor 
in the WIL cells and in some way make the host tissue 
more amendable to tumour take. The dexamethasone induced 
growth inhibition of WIL tumour was reversible as was 
found with murine mammary carcinoma (62). This indicates 
either a resistant fraction of the tumour to dexamethasone 
0 2} since growth inhibition appears to be due to inhibition 
of angiogenesisj there may exist two or more types of 
vasculature.
SUMMARY
The effect of dexamethasone on human non-small cell lung 
carcinoma in vitro and in vivo was investigated. 
Dexamethasone caused a significant reduction in growth rate 
in most of the cell lines at normal passage densities with 
the exception of H125 which had an increased growth rate 
in the presence of dexamethasone. In both cases the 
effect was dose dependent. Clonogenicity as a mono­
layer was increased by dexamethasone in all cell lines 
investigated except H125. Cloning efficiency in agar of 
all the cell lines examined was reduced by dexamethasone 
in a dose dependent manner. Significant levels of 
glucocorticoid receptor were found in all cell lines 
investigated. PA activity was lowered by dexamethasone 
in all cell lines except H125 where it was raised though 
not significantly.
Some alterations in cell surface carbohydrates were found 
to correlate with alterations in cell proliferation. The 
cell lines WIL and H125 were examined for mucin/GAG 
secretion but no mucin secretion was found. Both cell 
lines secreted hyaluronic acid only. Dexamethasone 
increased hyaluronic acid secretion by H125 and decreased 
it in WIL. Pulmonary surfactant synthesis and secretion 
was increased by dexamethasone in the als/aolar carcinoma 
A549.
Dexamethasone reduced the growth of the murine ROS tumour 
in vivo. The growth of WIL tumour was inhibited totally 
by dexamethasone in a reversible manner although pre­
treatment of WIL cells in vitro with dexamethasone increased 
the frequency of successful tumour takes.
Apparently dexamethasone could increase differentiation and 
reduce malignancy associated properties a manner which 
suggested they were inter-related. The expression of the
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differentiated phenotype is also correlated with a 
reduction in cell proliferation. Furthermore the in vivo 
response reflected the iu vitro response.
8 .1 The Effect of Dexamethasone Upon Malignancy Associated 
Properties
The effect of dexamethasone upon certain malignancy 
associated properties was investigated. PA activity was 
reduced in 5 out of 6 cell lines examined. The other cell 
line H125 had increased PA activity. In the assay used it 
is not possible to distinguish tPA from uPA but in one cell 
line examined no tPA was found.
Angiogenesis may also be reduced in vitro by dexamethasone. 
Conditioned medium from dexamethasone treated WIL and A549 
cells caused less stimulation of endothelial cells than 
control conditioned medium. However conditioned medium 
from the cell line H125 did not stimulate mitogenesis of 
endothelial cells. This indicates a possible deficiency 
in the system used. H125 is angiogenic in vivo but in 
vitro no mitogenic activity was detected. Thus the system 
may not detect certain tumour derived growth factors. 
Evidence also exists of dexamethasone "carry over" _ hich 
may interfere with the assay.
The effect of dexamethasone upon tumour cell surface 
glycopeptides was examined. As stated earlier an increase 
in sialylation and/or carbohydrate size accompanied an 
increase in malignancy associated properties. In this 
study it was found that this did not totally hold true.
With WIL which had a reduced PA activity with dexamethasone 
there was evidence of reduced sialylation in the presence 
of the drug and with A549 which also had a reduced PA 
activity with dexamethasone there was evidence of an 
increase, albeit low, in sialylation. There was no 
evidence of any alteration in H125 glycopeptides; this 
cell line had an increased PA activity in the presence of 
dexamethasone.
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Thus there is a slight correlation between dexamethasone 
modulation of PA activity and alteration in cell surface 
glycopeptides. Differences may arise due to the 
secretory function of the cells.
Clonogenicity in agar often accompanies malignant 
transformation. A reduction in clonogenicity in agar 
would therefore imply a reduction in malignancy. In the 
presence of dexamethasone it was found that the 
clonogenicity of the cell lines H125, WIL and A549 were 
reduced in a dose dependent manner. Most interesting 
was the fact that H125 had reduced clonogenicity while PA 
activity, angiogenic capacity and sialylation were either 
increased or unaffected by dexamethasone. This may be 
explained by the fact that dexamethasone reduces growth 
rate at clonal cell densities. This in turn may reduce 
colony size in agar.
In conclusion dexamethasone reduces malignancy associated
parameters of human non-small cell lung cancer in vitro.
One cell line, H125, appears to have increased malignancy
#
associated parameters in vitro but this is an exception.
8 .2 Effect of Dexamethasone on Differentiation
For some tissue types markers of differentiation are 
readily available e.g. melanin in melanocytes/melanoma. 
However for many tissues especially those of epithelial 
origin these markers are either not readily available or 
difficult to assay and lung cells fall into this category. 
The alveolar carcinoma A549 has a marker in pulmonary 
surfactant synthesis/secretion and in agreement with 
previous reports it was found that dexamethasone caused a 
significant increase in both synthesis and secretion of 
pulmonary surfactant. As stated earlier secretion of 
pulmonary surfactant is a better marker of differentiation 
of alveolar function since pulmonary surfactant components 
are found in membranes.
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Markers of differentiation for mucin secreting cells are 
more difficult to use since mucin/GAGs are highly
heterogeneous and their measurement is difficult. Using
complete and time consuming methods the presence and
quantity of these compounds can be ascertained, in both of
the cell lines investigated, H125 and WIL, no mucin 
secretion was found and the only GAG secreted was 
hyaluronic acid. It may be that for full differentiation 
a basement membrane is needed. As stated earlier (chapter 
5) mucin secretion and a decrease in hyaluronic acid 
secretion is indicative of differentiation.
When WIL was incubated with dexamethasone there was a 
significant reduction in hyaluronic acid secretion. An 
increase in hyaluronic acid secretion was seen with H125 
when incubated with dexamethasone. Thus dexamethasone 
appears to induce differentiation to an extent in WIL and 
de-differentiation in H125. Hyaluronic acid secretion 
seems to be related to proliferation; as the growth rate 
of WIL decreases hyaluronic acid secretion is reduced, 
while H125 has an increased growth rate and hyaluronic 
secretion in the presence of dexamethasone.
The experiments need to be repeated with a substratum 
present for the attainment of optimal induction of 
differentiation. Furthermore it may be worthwhile 
examining the effect of dexamethasone on trans-glutaminase 
activity and cross-linked envelope formation, two accepted 
markers of differentiation of the squamous phenotype.
8 .3 Inter-relationship between Malignancy and 
Differentiation
It has been proposed that malignancy and differentiation 
are inversely related; an increase in differentiation 
would be accompanied by a decrease in malignancy. It 
appears that this now also applies for human non-small cell 
lung cancer.
The cell line WIL had reduced malignancy associated 
parameters i.e. PA activity, angiogenic capacity, agar 
cloning and increased differentiation albeit partial i.e. 
hyaluronic acid secretion. The opposite effect applies 
for H125 when incubated with dexamethasone - dexamethasone 
causes an increase in malignancy associated parameters 
and a decrease in differentiation.
Furthermore with A549 dexamethasone induces differentiation 
(surfactant synthesis and secretion) and reduces 
malignancy (PA, agar cloning angiogenic capacity etc).
Thus in the case of human non-small cell lun^ cancer there 
appears to be an inverse correlation between differentiation 
and malignancy.
8 .4 Relationship between State of Differentiation and 
Cell Proliferation
'■'■I' ,
Dexamethasone can modulate proliferation. In 4 out of 6  
cell lines dexamethasone reduced proliferation while H125 
had an increased growth rate in the presence of the drug. 
These experiments were carried out at regular passage 
densities. This modulation of proliferation is 
accompanied by changes in phenotype
In the case of WIL the reduced growth rate in the presence 
of dexamethasone is accompanied by a decrease in hyaluronic 
acid secretion, PA activity, angiogenic capacity and 
clonogenicity in agar. Thus as differentiation is 
increased there is a decrease in proliferation. Although 
the effect of dexamethasone is reversed in H125 the 
relationship still holds. An increase in proliferation 
is accompanied by a decrease in differentiation.
Thus cytostasis correlates with differentiation while 
proliferation correlates with expression of malignancy.
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8.5 In Vivo Results
Dexamethasone significantly reduced the growth of ROS 
tumour in mice and abolished growth of WIL as an xenograft 
in nude mice. The growth of H125 xenograft was unaffected 
by dexamethasone. This result implies that the inhibition 
of tumour growth in vivo is cellular and not systemic.
The reason for the reduction in growth rate of WIL and 
lack of inhibition on H125 may be ascertained. Histology 
of dexamethasone treated WIL xenografts and in vito 
angiogenesis experiments using the cell line imply , a 
reduction in angiogenesis. It is possible that the 
inhibition of tumour growth may relate to a reduction in 
PA activity as reported by Mira-y-Lopez et al (62). 
Similarly the lack of inhibition of tumour growth in H125 
may relate to the lack of inhibition of PA in the cell 
line. The cytostatic effect of dexamethasone could also 
explain the reduced tumour growth in WIL.
The inhibition of growth of WIL as an xenograft is not due 
to a reduction in tumorigenicity. Pre-treated WIL cells 
in vitro when injected subcutaneously into nude mice showed 
a transient increase in tumour take relative controls.
This reversibility may be due to the reversibility of the 
actions of dexamethasone.
8.6 Future Experiments and Prospects
An interesting avenue would be to carry out many 
experiments with a natural substratum present to see if a 
greater increase in differentiation is obtained.
The combination of dexamethasone with conventional 
cytotoxic drugs in xenograft experiments may improve tumour 
growth inhibition and s u g g e s t  > a role for the steroid in 
the chemotherapy of human non-small cell lung cancer.
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